


up-to-date with a click!

IAS STATIN
NEWSLETTER



INTERNATIONAL
ATHEROSCLEROSIS
SOCIETY

A CURATED WEEKLY UPDATE OF ALL STATIN PUBLICATIONS

Update - December, 2021



Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.

The IAS statin literature update will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications December 2021

Add on treatments

1. Wan S, Ding Y, Ji X, Meng R. The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases. *Aging and disease* 2021; 12:1857-1871.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34881073>
2. Sunaga T, Ryo Y. Potential Safety Signals for Rhabdomyolysis Associated With High-Potency Statin Use With or Without Sacubitril/Valsartan. *Am J Cardiol* 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34963512>
3. Shin KH, Choi HD. Comparison of Efficacy and Safety of Statin-Ezetimibe Combination Therapy with Statin Monotherapy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Studies. *Am J Cardiovasc Drugs* 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34927215>
4. Jiang T, Xu L, Zhao M *et al*. Dual targeted delivery of statins and nucleic acids by chitosan-based nanoparticles for enhanced antiatherosclerotic efficacy. *Biomaterials* 2022; 280:121324. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34933253>
5. Samura M, Takada K, Hirose N *et al*. Incidence of elevated creatine phosphokinase between daptomycin alone and concomitant daptomycin and statins: A systematic review and meta-analysis. *Br J Clin Pharmacol* 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34902879>

6. Preiss D, Spata E, Holman RR *et al.* Effect of Fenofibrate Therapy on Laser Treatment for Diabetic Retinopathy: A Meta-Analysis of Randomized Controlled Trials. Diabetes Care 2022; 45:e1-e2. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34876531>
7. Gaitán-Duarte HG, Álvarez-Moreno C, Rincón-Rodríguez CJ *et al.* Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. EClinicalMedicine 2022; 43:101242. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957385>
8. Gao J, Liu JY, Lu PJ *et al.* Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol. Front Physiol 2021; 12:750872. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34887772>
9. Anwar S, Zaman M, Raja MAG *et al.* Rosuvastatin, Perindopril and Ezetimibe loaded instant release buccal films: Development and in vitro characterization. J Appl Biomed 2020; 18:115-125. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34907764>
10. Thongnak L, Pengrattanachot N, Promsan S *et al.* The combination of dapagliflozin and statins ameliorates renal injury through attenuating the activation of inflammasome-mediated autophagy in insulin-resistant rats. Journal of biochemical and molecular toxicology 2021:e22978. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34939712>
11. Kuhlman AB, Mikkelsen LB, Regnersgaard S *et al.* The effect of 8 weeks of physical training on muscle performance and maximal fat oxidation rates in patients treated with simvastatin and coenzyme Q10 supplementation. J Physiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34891216>
12. Chang R, Liu SY, Zhao LM. Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021; 100:e27802. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964748>
13. Du L, Jia JH, Xue WY, Qi JC. Effect of tadalafil combined with atorvastatin on hemodynamics and sexual function in middle-aged and elderly patients with hyperlipidemia complicated with erectile dysfunction. Pak J Med Sci 2021; 37:1965-1971. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34912427>
14. Sun Y, Yuan L, Liu X *et al.* Effects of atorvastatin and Zishen Qingqi granules on immune function and liver function of patients with systemic lupus erythematosus with mild and moderate activity. Pak J Pharm Sci 2021; 34:2085-2090. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34862878>
15. Tu Y, Zhang J, Zhang M *et al.* Effect of the therapy of amiodarone combined with atorvastatin on cardiac function of patients with acute myocardial infarction after percutaneous coronary intervention (PCI). Pak J Pharm Sci 2021; 34:2035-2040. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34862870>
16. Levintow SN, Orroth KK, Breskin A *et al.* Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies. Pharmacoepidemiol Drug Saf 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34894377>
17. Lee Y, Shin J, Kim Y, Kim DS. Consumption of single products versus fixed-dose combination medicines for hypertension and hyperlipidemia during 2015-2019 in South Korea. PLoS One 2021; 16:e0259467. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34910724>
18. Gnanenthiran SR, Agarwal A, Patel A. Frontiers of cardiovascular polypills: From atherosclerosis and beyond. Trends Cardiovasc Med 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973412>

Adherence

1. Rana JS, Virani SS, Moffet HH *et al.* Association of Low-Density Lipoprotein Testing After an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification. *Am J Med* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34861203>
2. Thompson W, Morin L, Jarbøl DE *et al.* Statin Discontinuation and Cardiovascular Events Among Older People in Denmark. *JAMA network open* 2021; 4:e2136802. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34854906>

Atherosclerosis – Plaque -Imaging

1. Liu M, Zhang Z, Zhao Y *et al.* Combining ultrasound with bio-indicators reveals progression of carotid stenosis. *Ann Palliat Med* 2021; 10:11539-11547. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34872279>
2. Adams A, Bojara W, Romanens M. Effect of Statin Treatment in Patients With Advanced Carotid Atherosclerosis: An Observational Outcome Study. *Cardiology research* 2021; 12:335-339. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970362>
3. Chevli PA, Freedman BI, Hsu FC *et al.* Plasma metabolomic profiling in subclinical atherosclerosis: the Diabetes Heart Study. *Cardiovascular diabetology* 2021; 20:231. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34876126>
4. Al Rifai M, Blaha MJ, Nambi V *et al.* Determinants of Incident Atherosclerotic Cardiovascular Disease Events Among Those With Absent Coronary Artery Calcium: Multi-Ethnic Study of Atherosclerosis. *Circulation* 2022; 145:259-267. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34879218>
5. Kraler S, Blaser MC, Aikawa E *et al.* Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy. *Eur Heart J* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34849696>
6. Wu Y, Li F, Wang Y *et al.* Standard-Dose Atorvastatin Treatment in Patients With Symptomatic Middle Cerebral Artery Atherosclerotic Stenosis: A Vessel Wall Magnetic Resonance Imaging Study. *Frontiers in neurology* 2021; 12:693397. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956036>
7. Suzuki Y, Matsumoto N, Yoda S *et al.* Coronary artery calcium score: Current status of clinical application and how to handle the results. *J Cardiol* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34895980>
8. Lee JS, Park SC, Kim SD. Effects of hypercholesterolemia on expansion of abdominal aortic aneurysm in rat model. *Journal of cardiothoracic surgery* 2021; 16:352. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961565>
9. Hashimoto T, Minami Y, Asakura K *et al.* Lower levels of low-density lipoprotein cholesterol are associated with a lower prevalence of thin-cap fibroatheroma in statin-treated patients with coronary artery disease. *J Clin Lipidol* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34924352>
10. Cainzos-Achirica M, Quispe R, Dudum R *et al.* CAC for Risk Stratification Among Individuals With Hypertriglyceridemia Free of Clinical Atherosclerotic Cardiovascular Disease. *JACC. Cardiovascular imaging* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34922873>
11. Muhlestein JB, Knowlton KU, Le VT *et al.* Coronary Artery Calcium Versus Pooled Cohort Equations Score for Primary Prevention Guidance: Randomized Feasibility Trial. *JACC. Cardiovascular imaging* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34922872>

12. Zhang L, Olalere D, Mayrhofer T *et al.* Differences in Cardiovascular Risk, Coronary Artery Disease, and Cardiac Events Between Black and White Individuals Enrolled in the PROMISE Trial. JAMA cardiology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34935857>
13. Kononov S, Mal G, Azarova I *et al.* Pharmacogenetic loci for rosuvastatin are associated with intima-media thickness change and coronary artery disease risk. Pharmacogenomics 2022; 23:15-34. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34905955>

Atorvastatin/Rosuvastatin

1. Yu Y, Zhang YH, Liu L *et al.* Bioinformatics analysis of candidate genes and potential therapeutic drugs targeting adipose tissue in obesity. Adipocyte 2022; 11:1-10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964707>
2. Sunaga T, Ryo Y. Potential Safety Signals for Rhabdomyolysis Associated With High-Potency Statin Use With or Without Sacubitril/Valsartan. Am J Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963512>
3. Wesolowska A, Winiarska H, Owoc J *et al.* Effects of Low-Dose Atorvastatin on the Peripheral Blood Mononuclear Cell Secretion of Angiogenic Factors in Type 2 Diabetes. Biomolecules 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34944529>
4. Radyukhina NV, Ruleva NY, Filatova AY, Aref'eva TI. Inhibitors of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (Statins) Suppress Proliferation and Motility of Human CD4(+) T Lymphocytes in Culture. Bulletin of experimental biology and medicine 2021; 172:137-142. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34855095>
5. Cui M, Zhu F, Yin Y *et al.* Influence of Gegenqinlian Decoction on Pharmacokinetics and Pharmacodynamics of Atorvastatin Calcium in Hyperlipidemic Rats. European journal of drug metabolism and pharmacokinetics 2022; 47:117-126. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34855161>
6. Park J, Kang H, Choi YS *et al.* Prevention of Intra-Abdominal Adhesions Using the Combination of Mediclore® and a Statin. Eur Surg Res 2021:1-9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34864732>
7. Marchianò S, Biagioli M, Roselli R *et al.* Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2022; 36:e22060. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34862975>
8. Wu Y, Li F, Wang Y *et al.* Standard-Dose Atorvastatin Treatment in Patients With Symptomatic Middle Cerebral Artery Atherosclerotic Stenosis: A Vessel Wall Magnetic Resonance Imaging Study. Frontiers in neurology 2021; 12:693397. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956036>
9. Hwang S, Ko JW, Lee H *et al.* Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects. Frontiers in pharmacology 2021; 12:754849. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34867368>
10. Silveira AMR, Duarte GHB, Fernandes A *et al.* Serum Predose Metabolic Profiling for Prediction of Rosuvastatin Pharmacokinetic Parameters in Healthy Volunteers. Frontiers in pharmacology 2021; 12:752960. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34867363>
11. Kidambi BR, Purohit V, Bajpai S *et al.* Is the use of high-intensity atorvastatin associated with memory impairment? Indian Heart J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34933015>

12. Katanasaka Y, Hirano S, Sunagawa Y *et al.* Clinically Administered Doses of Pitavastatin and Rosuvastatin. Int Heart J 2021; 62:1379-1386.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34853228>
13. Akbarian R, Chamanara M, Rashidian A *et al.* Atorvastatin prevents the development of diabetic neuropathic nociception by possible involvement of nitrenergic system. J Appl Biomed 2021; 19:48-56. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34907715>
14. Anwar S, Zaman M, Raja MAG *et al.* Rosuvastatin, Perindopril and Ezetimibe loaded instant release buccal films: Development and in vitro characterization. J Appl Biomed 2020; 18:115-125. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34907764>
15. Kiage J, Venkatanarayan A, Roth M, Elam M. Atorvastatin-associated rhabdomyolysis in a patient with a novel variant of the SLCO1B1 gene: A case report. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34887219>
16. Wang Y, Zhou C, Yu T, Zhao F. Correlation between Changes in Serum RBP4, hs-CRP, and IL-27 Levels and Rosuvastatin in the Treatment of Coronary Heart Disease. J Healthc Eng 2021; 2021:8476592. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956579>
17. Mehrabi S, Torkan J, Hosseinzadeh M. Effect of atorvastatin on serum periostin and blood eosinophils in asthma - a placebo-controlled randomized clinical trial. J Int Med Res 2021; 49:3000605211063721. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34904467>
18. Naville-Cook C, Rhea L, Triboletti M, White C. Analyzing the Clinical Outcomes of a Rapid Mass Conversion From Rosuvastatin to Atorvastatin in a VA Medical Center Outpatient Setting. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians 2017; 33:189-194.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34860938>
19. De Giorgi R, Martens M, Rizzo Pesci N *et al.* The effects of atorvastatin on emotional processing, reward learning, verbal memory and inflammation in healthy volunteers: An experimental medicine study. Journal of psychopharmacology (Oxford, England) 2021; 35:1479-1487. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34872404>
20. Ramberg C, Hindberg K, Biedermann JS *et al.* Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial. Journal of thrombosis and haemostasis : JTH 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34953155>
21. Atorvastatin. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
22. Rosuvastatin. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
23. Wu L, Cheng Y, Peng S *et al.* Sphingosine Kinase 1 Plays an Important Role in Atorvastatin-Mediated Anti-Inflammatory Effect against Acute Lung Injury. Mediators Inflamm 2021; 2021:9247285. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970075>
24. Sun Y, Yuan L, Liu X *et al.* Effects of atorvastatin and Zishen Qingqi granules on immune function and liver function of patients with systemic lupus erythematosus with mild and moderate activity. Pak J Pharm Sci 2021; 34:2085-2090.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34862878>
25. Tu Y, Zhang J, Zhang M *et al.* Effect of the therapy of amiodarone combined with atorvastatin on cardiac function of patients with acute myocardial infarction after percutaneous coronary intervention (PCI). Pak J Pharm Sci 2021; 34:2035-2040.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34862870>
26. Al-Hashimi NN, Shtaiwi MH, Hamed SH *et al.* Development of Diocetyl Phthalate@Fe(3)O(4) Nanocomposite Reinforced Hollow Fiber Solid/ Liquid Phase

Microextraction Followed by HPLC-DAD for the Determination of Atorvastatin and Gemfibrozil in Human Urine. *Pharm Nanotechnol* 2021; 9:372-382.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=34951377>

27. Kononov S, Mal G, Azarova I *et al.* Pharmacogenetic loci for rosuvastatin are associated with intima-media thickness change and coronary artery disease risk. *Pharmacogenomics* 2022; 23:15-34. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34905955>
28. Postolache TT, Medoff DR, Brown CH *et al.* Lipophilic vs. hydrophilic statins and psychiatric hospitalizations and emergency room visits in US Veterans with schizophrenia and bipolar disorder. *Pteridines* 2021; 32:48-69. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34887622>
29. Jiang RC, Wang D, Zhao SG *et al.* Atorvastatin combined with dexamethasone in chronic subdural haematoma (ATOCH II): study protocol for a randomized controlled trial. *Trials* 2021; 22:905. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34895306>

Basic science

1. Sambamoorthy U, Manjappa AS, Eswara BRM *et al.* Vitamin E Oil Incorporated Liposomal Melphalan and Simvastatin: Approach to Obtain Improved Physicochemical Characteristics of Hydrolysable Melphalan and Anticancer Activity in Combination with Simvastatin Against Multiple Myeloma. *AAPS PharmSciTech* 2021; 23:23. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34907484>
2. Yu Y, Zhang YH, Liu L *et al.* Bioinformatics analysis of candidate genes and potential therapeutic drugs targeting adipose tissue in obesity. *Adipocyte* 2022; 11:1-10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964707>
3. Cai Y, Zhao F. Fluvastatin suppresses the proliferation, invasion, and migration and promotes the apoptosis of endometrial cancer cells by upregulating Sirtuin 6 (SIRT6). *Bioengineered* 2021; 12:12509-12520. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34927546>
4. Tian H, Qiang T, Wang J *et al.* Simvastatin regulates the proliferation, apoptosis, migration and invasion of human acute myeloid leukemia cells via miR-19a-3p/HIF-1 α axis. *Bioengineered* 2021; 12:11898-11908. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34895042>
5. Jiang T, Xu L, Zhao M *et al.* Dual targeted delivery of statins and nucleic acids by chitosan-based nanoparticles for enhanced antiatherosclerotic efficacy. *Biomaterials* 2022; 280:121324. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34933253>
6. Zhang Y, He J, Tang X *et al.* A validated LC-MS/MS method for simultaneous quantification of simvastatin and simvastatin acid in beagle plasma: Application to an absolute bioavailability study. *Biomedical chromatography : BMC* 2021:e5290. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34854096>
7. Ni Q, Chen H, Li W *et al.* Corrigendum to "Pravastatin ameliorated osteoarthritis susceptibility in male offspring rats induced by prenatal ethanol exposure" (Bone 149 (2021) 115976). *Bone* 2022; 155:116288. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34893461>
8. Elakkad YE, Mohamed SNS, Abuelezz NZ. Potentiating the Cytotoxic Activity of a Novel Simvastatin-Loaded Cubosome against Breast Cancer Cells: Insights on Dual Cell Death via Ferroptosis and Apoptosis. *Breast cancer (Dove Medical Press)* 2021; 13:675-689. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34934357>
9. Radyukhina NV, Ruleva NY, Filatova AY, Aref'eva TI. Inhibitors of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (Statins) Suppress Proliferation and Motility

- of Human CD4(+) T Lymphocytes in Culture. Bulletin of experimental biology and medicine 2021; 172:137-142. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34855095>
10. Goldberg H, Mohsin FK, Chandrasekar T *et al.* The association of statin subgroups with lower urinary tract symptoms following a prostate biopsy. Can Urol Assoc J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34941486>
 11. Chevli PA, Freedman BI, Hsu FC *et al.* Plasma metabolomic profiling in subclinical atherosclerosis: the Diabetes Heart Study. Cardiovascular diabetology 2021; 20:231. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34876126>
 12. Taruselli MT, Kolawole EM, Qayum AA *et al.* Fluvastatin enhances IL-33-mediated mast cell IL-6 and TNF production. Cell Immunol 2022; 371:104457. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34883342>
 13. Jakab J, Zjalić M, Mikšić Š *et al.* Effect of Metformin and Simvastatin in Inhibiting Preadipogenic Transcription Factors. Curr Issues Mol Biol 2021; 43:2082-2097. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34940118>
 14. Seydametova E, Zainol N. Morphological, physiological, biochemical and molecular characterization of statin-producing *Penicillium* microfungi isolated from little-explored tropical ecosystems. Curr Res Microb Sci 2021; 2:100044. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34841335>
 15. Cui M, Zhu F, Yin Y *et al.* Influence of Gegenqinlian Decoction on Pharmacokinetics and Pharmacodynamics of Atorvastatin Calcium in Hyperlipidemic Rats. European journal of drug metabolism and pharmacokinetics 2022; 47:117-126. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34855161>
 16. Pohlen M, Aguiar Zdovc J, Trontelj J *et al.* Relative bioavailability enhancement of simvastatin via dry emulsion systems: comparison of spray drying and fluid bed layering technology. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34942336>
 17. Ding L, Chen Q, Chen K *et al.* Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation. Eur J Pharmacol 2021; 913:174633. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34843676>
 18. Marchianò S, Biagioli M, Roselli R *et al.* Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2022; 36:e22060. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34862975>
 19. Silveira AMR, Duarte GHB, Fernandes A *et al.* Serum Predose Metabolic Profiling for Prediction of Rosuvastatin Pharmacokinetic Parameters in Healthy Volunteers. Frontiers in pharmacology 2021; 12:752960. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34867363>
 20. Katanasaka Y, Hirano S, Sunagawa Y *et al.* Clinically Administered Doses of Pitavastatin and Rosuvastatin. Int Heart J 2021; 62:1379-1386. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34853228>
 21. Mottaghitalab F, Motasadizadeh H, Shokrgozar MA *et al.* Fabrication of Silk Scaffold Containing Simvastatin-Loaded Silk Fibroin Nanoparticles for Regenerating Bone Defects. Iranian biomedical journal 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34875820>
 22. Ábrego-Gacía A, Poggi-Varaldo HM, Robles-González V *et al.* Lovastatin as a supplement to mitigate rumen methanogenesis: an overview. J Anim Sci Biotechnol 2021; 12:123. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34911584>

23. Anwar S, Zaman M, Raja MAG *et al.* Rosuvastatin, Perindopril and Ezetimibe loaded instant release buccal films: Development and in vitro characterization. J Appl Biomed 2020; 18:115-125. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34907764>
24. Lee JS, Park SC, Kim SD. Effects of hypercholesterolemia on expansion of abdominal aortic aneurysm in rat model. Journal of cardiothoracic surgery 2021; 16:352. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961565>
25. Salem WA, Elkady EF, Fouad MA, Mohammad MA. DoE Screening and Optimization of Liquid Chromatographic Determination of Nicotinic Acid and Six Statins: Application to Pharmaceutical Preparations and Counterfeit Detection. Journal of chromatographic science 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34894146>
26. Mohapatra D, Das B, Suresh V *et al.* Correction to: Fluvastatin sensitizes pancreatic cancer cells toward radiation therapy and suppresses radiation- and/or TGF- β -induced tumor-associated fibrosis. Lab Invest 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34853441>
27. Gouni S, Strati P, Toruner G *et al.* Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma. Leukemia & lymphoma 2021:1-12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969327>
28. Abdel-Bakky MS, Alqasoumi A, Altowayan WM *et al.* Simvastatin mitigates streptozotocin-induced type 1 diabetes in mice through downregulation of ADAM10 and ADAM17. Life sciences 2022; 289:120224. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34896343>
29. Al-Hashimi NN, Shtaiwi MH, Hamed SH *et al.* Development of Diocetyl Phthalate@Fe(3)O(4) Nanocomposite Reinforced Hollow Fiber Solid/ Liquid Phase Microextraction Followed by HPLC-DAD for the Determination of Atorvastatin and Gemfibrozil in Human Urine. Pharm Nanotechnol 2021; 9:372-382. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34951377>
30. Nakayama H, Sekine Y, Oka D *et al.* Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer. Prostate 2022; 82:314-322. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34843630>
31. Vigneau AL, Rico C, Boerboom D, Paquet M. Statins downregulate YAP and TAZ and exert anti-cancer effects in canine mammary tumour cells. Vet Comp Oncol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34881506>

Cancer

1. Sambamoorthy U, Manjappa AS, Eswara BRM *et al.* Vitamin E Oil Incorporated Liposomal Melphalan and Simvastatin: Approach to Obtain Improved Physicochemical Characteristics of Hydrolysable Melphalan and Anticancer Activity in Combination with Simvastatin Against Multiple Myeloma. AAPS PharmSciTech 2021; 23:23. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34907484>
2. Li Y, Chen S, Zhu J *et al.* Lovastatin enhances chemosensitivity of paclitaxel-resistant prostate cancer cells through inhibition of CYP2C8. Biochem Biophys Res Commun 2022; 589:85-91. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34896780>
3. Cai Y, Zhao F. Fluvastatin suppresses the proliferation, invasion, and migration and promotes the apoptosis of endometrial cancer cells by upregulating Sirtuin 6 (SIRT6). Bioengineered 2021; 12:12509-12520. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34927546>
4. Tian H, Qiang T, Wang J *et al.* Simvastatin regulates the proliferation, apoptosis, migration and invasion of human acute myeloid leukemia cells via miR-19a-3p/HIF-1 α axis. Bioengineered 2021; 12:11898-11908. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34895042>

5. Elakkad YE, Mohamed SNS, Abuelezz NZ. Potentiating the Cytotoxic Activity of a Novel Simvastatin-Loaded Cubosome against Breast Cancer Cells: Insights on Dual Cell Death via Ferroptosis and Apoptosis. Breast cancer (Dove Medical Press)_2021; 13:675-689. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34934357>
6. Goldberg H, Mohsin FK, Chandrasekar T *et al.* The association of statin subgroups with lower urinary tract symptoms following a prostate biopsy. Can Urol Assoc J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34941486>
7. Seo SI, Park CH, Kim TJ *et al.* Aspirin, metformin, and statin use on the risk of gastric cancer: A nationwide population-based cohort study in Korea with systematic review and meta-analysis. Cancer medicine 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970858>
8. Chen Y, Han L, Zheng A. Association between statin use and the risk, prognosis of gynecologic cancer: A meta-analysis. Eur J Obstet Gynecol Reprod Biol 2022; 268:74-81. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34875557>
9. Ding L, Chen Q, Chen K *et al.* Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation. Eur J Pharmacol 2021; 913:174633. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34843676>
10. Chen PH, Jhou HJ, Chung CH *et al.* The Effect of Statins in Cancer Risk Reduction in Patients on Dialysis: A Population-Based Case-Control Study. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34884304>
11. Patnaik SK, Petrucci C, Barbi J *et al.* Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC. JTO Clin Res Rep 2021; 2:100254. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34877556>
12. Mohapatra D, Das B, Suresh V *et al.* Correction to: Fluvastatin sensitizes pancreatic cancer cells toward radiation therapy and suppresses radiation- and/or TGF- β -induced tumor-associated fibrosis. Lab Invest 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34853441>
13. Gouni S, Strati P, Toruner G *et al.* Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma. Leukemia & lymphoma 2021:1-12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969327>
14. Bourguillon RO, Stokes WA, Dorth J, Schmitt NC. Repurposing Statin Drugs to Decrease Toxicity and Improve Survival Outcomes in Head and Neck Cancer. OTO Open 2021; 5:2473974x211065715. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34917872>
15. Grabarek BO, Boroń D, Morawiec E *et al.* Crosstalk between Statins and Cancer Prevention and Therapy: An Update. Pharmaceuticals (Basel, Switzerland)_2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959621>
16. Kwon MJ, Kang HS, Kim JH *et al.* Association between Statin Use and Gastric Cancer: A Nested Case-Control Study Using a National Health Screening Cohort in Korea. Pharmaceuticals (Basel, Switzerland)_2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959682>
17. Nakayama H, Sekine Y, Oka D *et al.* Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer. Prostate 2022; 82:314-322. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34843630>
18. Vigneau AL, Rico C, Boerboom D, Paquet M. Statins downregulate YAP and TAZ and exert anti-cancer effects in canine mammary tumour cells. Vet Comp Oncol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34881506>

Cost-effectiveness

1. Okunrintemi V, Valero-Elizondo J, Stone NJ *et al.* Shared decision making and patient reported outcomes among adults with atherosclerotic cardiovascular disease, medical expenditure panel survey 2006-2015. Am J Prev Cardiol 2021; 8:100281. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34877558>

CVD

1. Wan S, Ding Y, Ji X, Meng R. The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases. Aging and disease 2021; 12:1857-1871. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34881073>
2. Rana JS, Virani SS, Moffet HH *et al.* Association of Low-Density Lipoprotein Testing After an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification. Am J Med 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34861203>
3. Nguyen HT, Ha KPT, Nguyen AH *et al.* Non-achievement of the Low-Density Lipoprotein Cholesterol Goal in Older Patients with Type 2 Diabetes Mellitus and a Very High Cardiovascular Disease Risk: A Multicenter Study in Vietnam. Ann Geriatr Med Res 2021; 25:278-285. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34865341>
4. Shrauner W, Lord EM, Nguyen XT *et al.* Frailty and cardiovascular mortality in more than 3 million US Veterans. Eur Heart J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34907422>
5. White HD, Schwartz GG, Szarek M *et al.* Alirocumab after acute coronary syndrome in patients with a history of heart failure. Eur Heart J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34922353>
6. Zhang WT, Wang XJ, Xue CM *et al.* The Effect of Cardiovascular Medications on Disease-Related Outcomes in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Frontiers in pharmacology 2021; 12:771804. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34858190>
7. Ishii J, Kashiwabara K, Ozaki Y *et al.* Small Dense Low-Density Lipoprotein Cholesterol and Cardiovascular Risk in Statin-Treated Patients with Coronary Artery Disease. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34880156>
8. McKinley EC, Bittner VA, Brown TM *et al.* Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34848176>
9. Wang Y, Zhou C, Yu T, Zhao F. Correlation between Changes in Serum RBP4, hs-CRP, and IL-27 Levels and Rosuvastatin in the Treatment of Coronary Heart Disease. J Healthc Eng 2021; 2021:8476592. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956579>
10. Pan E, Nielsen SJ, Mennander A *et al.* Statins for secondary prevention and major adverse events after coronary artery bypass grafting. The Journal of thoracic and cardiovascular surgery 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34893327>
11. Zhang L, Olalere D, Mayrhofer T *et al.* Differences in Cardiovascular Risk, Coronary Artery Disease, and Cardiac Events Between Black and White Individuals Enrolled in the PROMISE Trial. JAMA cardiology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34935857>
12. Thompson W, Morin L, Jarbøl DE *et al.* Statin Discontinuation and Cardiovascular Events Among Older People in Denmark. JAMA network open 2021; 4:e2136802. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34854906>
13. Tu Y, Zhang J, Zhang M *et al.* Effect of the therapy of amiodarone combined with atorvastatin on cardiac function of patients with acute myocardial infarction after

percutaneous coronary intervention (PCI). Pak J Pharm Sci 2021; 34:2035-2040.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=34862870>

14. Eggers KM, Jernberg T, Lindahl B. Risk-associated management disparities in acute myocardial infarction. Scientific reports 2021; 11:24488.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=34966178>

15. Siostrzonek P, Brath H, Zweiker R *et al.* Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study. Wien Klin Wochenschr 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34870742>

Endothelium/inflammation

1. Radyukhina NV, Ruleva NY, Filatova AY, Aref'eva TI. Inhibitors of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (Statins) Suppress Proliferation and Motility of Human CD4(+) T Lymphocytes in Culture. Bulletin of experimental biology and medicine 2021; 172:137-142. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34855095>

2. Taruselli MT, Kolawole EM, Qayum AA *et al.* Fluvastatin enhances IL-33-mediated mast cell IL-6 and TNF production. Cell Immunol 2022; 371:104457.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=34883342>

3. Satny M, Hubacek JA, Vrablik M. Statins and Inflammation. Curr Atheroscler Rep 2021; 23:80. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34851454>

4. Wu L, Cheng Y, Peng S *et al.* Sphingosine Kinase 1 Plays an Important Role in Atorvastatin-Mediated Anti-Inflammatory Effect against Acute Lung Injury. Mediators Inflamm 2021; 2021:9247285. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970075>

Ethnicity

1. Seo SI, Park CH, Kim TJ *et al.* Aspirin, metformin, and statin use on the risk of gastric cancer: A nationwide population-based cohort study in Korea with systematic review and meta-analysis. Cancer medicine 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970858>

2. Gao J, Liu JY, Lu PJ *et al.* Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol. Front Physiol 2021; 12:750872. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34887772>

3. Zhang L, Olalere D, Mayrhofer T *et al.* Differences in Cardiovascular Risk, Coronary Artery Disease, and Cardiac Events Between Black and White Individuals Enrolled in the PROMISE Trial. JAMA cardiology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34935857>

4. Shen L, Qiu L, Wang L *et al.* Statin Use and In-hospital Mortality in Patients with COVID-19 and Coronary Heart Disease. Scientific reports 2021; 11:23874. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34903765>

5. Min HK, Kim SH, Choi JH *et al.* Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data. World journal of clinical cases 2021; 9:10198-10207. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34904090>

FH

1. Eid WE, Sapp EH, Wendt A *et al.* Improving Familial Hypercholesterolemia Diagnosis Using an EMR-based Hybrid Diagnostic Model. J Clin Endocrinol Metab 2021.

Genetics

1. Kiage J, Venkatanarayan A, Roth M, Elam M. Atorvastatin-associated rhabdomyolysis in a patient with a novel variant of the SLCO1B1 gene: A case report. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34887219>
2. Patnaik SK, Petrucci C, Barbi J *et al.* Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC. JTO Clin Res Rep 2021; 2:100254. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34877556>
3. Kononov S, Mal G, Azarova I *et al.* Pharmacogenetic loci for rosuvastatin are associated with intima-media thickness change and coronary artery disease risk. Pharmacogenomics 2022; 23:15-34. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34905955>
4. Xi N, Wang Y, Zhou J *et al.* (Influence of ApoE gene polymorphisms on therapeutic effects of lipid-lowering statins among patients with ischemic cerebral infarction). Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2022; 39:94-98. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964977>

Guidelines

1. Gobbel GT, Matheny ME, Reeves RR *et al.* Leveraging structured and unstructured electronic health record data to detect reasons for suboptimal statin therapy use in patients with atherosclerotic cardiovascular disease. Am J Prev Cardiol 2022; 9:100300. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950914>
2. Mortensen MB, Nordestgaard BG. Guidelines versus trial-evidence for statin use in primary prevention: The Copenhagen General Population Study. Atherosclerosis 2022; 341:20-26. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959205>
3. Butalia S, Chen G, Duan Q, Anderson TJ. Care gaps in achieving cholesterol targets in people with diabetes: a population-based study in a universal health care setting. Diabetes Res Clin Pract 2021:109177. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34923023>
4. Taha H, Kandil H, Farag N *et al.* Egyptian practical guidance in hypertriglyceridemia management 2021. The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology 2021; 73:107. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34928475>
5. Cecha P, Chromik A, Piotrowska I *et al.* Assessment of application of the new 2019 European Society of Cardiology/ European Atherosclerosis Society Guidelines for the Management of Dyslipidaemias in daily clinical practice - one center study. Folia Med Cracov 2021; 61:43-54. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34882663>
6. Suzuki Y, Matsumoto N, Yoda S *et al.* Coronary artery calcium score: Current status of clinical application and how to handle the results. J Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34895980>
7. Muhlestein JB, Knowlton KU, Le VT *et al.* Coronary Artery Calcium Versus Pooled Cohort Equations Score for Primary Prevention Guidance: Randomized Feasibility Trial. JACC. Cardiovascular imaging 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34922872>
8. Siostrzonek P, Brath H, Zweiker R *et al.* Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study. Wien Klin Wochenschr 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34870742>

9. Guo YF. (Improving the prevention and treatment of cardiovascular disease through strictly controlling the risk factors: interpretation of the 2021 ESC clinical practice guide for cardiovascular disease prevention). Zhonghua xin xue guan bing za zhi 2021; 49:1244-1246. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34905905>

LDL- related parameters

1. Rana JS, Virani SS, Moffet HH *et al.* Association of Low-Density Lipoprotein Testing After an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification. Am J Med 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34861203>
2. Gobbel GT, Matheny ME, Reeves RR *et al.* Leveraging structured and unstructured electronic health record data to detect reasons for suboptimal statin therapy use in patients with atherosclerotic cardiovascular disease. Am J Prev Cardiol 2022; 9:100300. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950914>
3. Nguyen HT, Ha KPT, Nguyen AH *et al.* Non-achievement of the Low-Density Lipoprotein Cholesterol Goal in Older Patients with Type 2 Diabetes Mellitus and a Very High Cardiovascular Disease Risk: A Multicenter Study in Vietnam. Ann Geriatr Med Res 2021; 25:278-285. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34865341>
4. Mortensen MB, Nordestgaard BG. Guidelines versus trial-evidence for statin use in primary prevention: The Copenhagen General Population Study. Atherosclerosis 2022; 341:20-26. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959205>
5. Lv Y, Xu B, Zhang X *et al.* Association of serum cholesterol with Parkinson's disease in a cohort of statin-free individuals. Brain and behavior 2022; 12:e2454. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34894416>
6. Bermudez-Lopez M, Perpiñan H, Amigo N *et al.* Advanced lipoprotein parameters could better explain atheromatosis in non-diabetic chronic kidney disease patients. Clinical kidney journal 2021; 14:2591-2599. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950470>
7. Butalia S, Chen G, Duan Q, Anderson TJ. Care gaps in achieving cholesterol targets in people with diabetes: a population-based study in a universal health care setting. Diabetes Res Clin Pract 2021:109177. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34923023>
8. Cui M, Zhu F, Yin Y *et al.* Influence of Gegenqinlian Decoction on Pharmacokinetics and Pharmacodynamics of Atorvastatin Calcium in Hyperlipidemic Rats. European journal of drug metabolism and pharmacokinetics 2022; 47:117-126. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34855161>
9. de Boer LM, Oorthuys AOJ, Wiegman A *et al.* Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. Eur J Prev Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34849724>
10. van der Laarse A, Cobbaert CM. Biochemical risk factors of atherosclerotic cardiovascular disease: from a narrow and controversial approach to an integral approach and precision medicine. Expert Rev Cardiovasc Ther 2021; 19:1085-1096. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34937476>
11. Ishii J, Kashiwabara K, Ozaki Y *et al.* Small Dense Low-Density Lipoprotein Cholesterol and Cardiovascular Risk in Statin-Treated Patients with Coronary Artery Disease. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34880156>
12. Lee JS, Park SC, Kim SD. Effects of hypercholesterolemia on expansion of abdominal aortic aneurysm in rat model. Journal of cardiothoracic surgery 2021; 16:352. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961565>

13. Hashimoto T, Minami Y, Asakura K *et al.* Lower levels of low-density lipoprotein cholesterol are associated with a lower prevalence of thin-cap fibroatheroma in statin-treated patients with coronary artery disease. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34924352>
14. Lee C, Park JT, Chang TI *et al.* Low-density lipoprotein cholesterol levels and adverse clinical outcomes in chronic kidney disease: Results from the KNOW-CKD. Nutrition, metabolism, and cardiovascular diseases : NMCD 2022; 32:410-419. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34893405>
15. Weng SF, Akyea RK, Man KK *et al.* Determining propensity for sub-optimal low-density lipoprotein cholesterol response to statins and future risk of cardiovascular disease. PLoS One 2021; 16:e0260839. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34855879>
16. Siostrzonek P, Brath H, Zweiker R *et al.* Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study. Wien Klin Wochenschr 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34870742>
17. Xi N, Wang Y, Zhou J *et al.* (Influence of ApoE gene polymorphisms on therapeutic effects of lipid-lowering statins among patients with ischemic cerebral infarction). Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2022; 39:94-98. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964977>

Lifestyle

1. Righetti L, Dall'Asta C, Bruni R. Risk Assessment of RYR Food Supplements: Perception vs. Reality. Front Nutr 2021; 8:792529. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950692>

Meta-analyses

1. Shin KH, Choi HD. Comparison of Efficacy and Safety of Statin-Ezetimibe Combination Therapy with Statin Monotherapy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Studies. Am J Cardiovasc Drugs 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34927215>
2. Lv J, Ren C, Hu Q. Effect of statins on the treatment of early diabetic nephropathy: a systematic review and meta-analysis of nine randomized controlled trials. Ann Palliat Med 2021; 10:11548-11557. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34872280>
3. Samura M, Takada K, Hirose N *et al.* Incidence of elevated creatine phosphokinase between daptomycin alone and concomitant daptomycin and statins: A systematic review and meta-analysis. Br J Clin Pharmacol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34902879>
4. Athyros VG, Katsiki N, Mikhailidis DP. Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis: RE: Fatima K, Moeed A, Waqar E, Atif AR, Kamran A, Rizvi H, Suri NF, Haider H, Shuja SH, Khalid M, Minhas AMK. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2021 Oct 1:101816. doi: 10.1016/j.clinre.2021.101816. Epub ahead of print. PMID:34607067. Clin Res Hepatol Gastroenterol 2021:101842. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34920141>
5. Tully PJ, Ang SY, Lee EJ *et al.* Psychological and pharmacological interventions for depression in patients with coronary artery disease. The Cochrane database of

- systematic reviews 2021; 12:Cd008012. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34910821>
6. Volpe M, Patrono C. The cardiovascular benefits of statins outweigh adverse effects in primary prevention: results of a large systematic review and meta-analysis. Eur Heart J 2021; 42:4518-4519. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34849717>
 7. Chen Y, Han L, Zheng A. Association between statin use and the risk, prognosis of gynecologic cancer: A meta-analysis. Eur J Obstet Gynecol Reprod Biol 2022; 268:74-81. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34875557>
 8. de Boer LM, Oorthuys AOJ, Wiegman A *et al.* Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. Eur J Prev Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34849724>
 9. Olmastroni E, Molari G, De Beni N *et al.* Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies. Eur J Prev Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34871380>
 10. Feng X, Tang Q, Cheng C, Xu S. Low serum lipid levels, use of statin and cerebral microbleeds: A systematic review and meta-analysis. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2021; 94:216-225. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34863441>
 11. Chang R, Liu SY, Zhao LM. Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021; 100:e27802. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964748>
 12. Zhang L, Bao Y, Tao S *et al.* The association between cardiovascular drugs and depression/anxiety in patients with cardiovascular disease: A meta-analysis. Pharmacol Res 2022; 175:106024. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34890773>
 13. Chen J, Huang C, Zhang T *et al.* The effects of statins on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive biology and endocrinology : RB&E 2021; 19:189. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34930305>

Metabolic Syndrome - Diabetes

1. Shin KH, Choi HD. Comparison of Efficacy and Safety of Statin-Ezetimibe Combination Therapy with Statin Monotherapy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Studies. Am J Cardiovasc Drugs 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34927215>
2. Nguyen HT, Ha KPT, Nguyen AH *et al.* Non-achievement of the Low-Density Lipoprotein Cholesterol Goal in Older Patients with Type 2 Diabetes Mellitus and a Very High Cardiovascular Disease Risk: A Multicenter Study in Vietnam. Ann Geriatr Med Res 2021; 25:278-285. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34865341>
3. Wesolowska A, Winiarska H, Owoc J *et al.* Effects of Low-Dose Atorvastatin on the Peripheral Blood Mononuclear Cell Secretion of Angiogenic Factors in Type 2 Diabetes. Biomolecules 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34944529>
4. Chevli PA, Freedman BI, Hsu FC *et al.* Plasma metabolomic profiling in subclinical atherosclerosis: the Diabetes Heart Study. Cardiovascular diabetology 2021; 20:231. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34876126>
5. Preiss D, Spata E, Holman RR *et al.* Effect of Fenofibrate Therapy on Laser Treatment for Diabetic Retinopathy: A Meta-Analysis of Randomized Controlled Trials. Diabetes Care 2022; 45:e1-e2. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34876531>

6. Butalia S, Chen G, Duan Q, Anderson TJ. Care gaps in achieving cholesterol targets in people with diabetes: a population-based study in a universal health care setting. Diabetes Res Clin Pract 2021;109177. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34923023>
7. Felder M, Maushart CI, Gashi G *et al.* Fluvastatin Reduces Glucose Tolerance in Healthy Young Individuals Independently of Cold Induced BAT Activity. Frontiers in endocrinology 2021; 12:765807. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34858338>
8. Akbarian R, Chamanara M, Rashidian A *et al.* Atorvastatin prevents the development of diabetic neuropathic nociception by possible involvement of nitregeric system. J Appl Biomed 2021; 19:48-56. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34907715>
9. Slomski A. Statin Use Is Associated With Diabetes Progression. Jama 2021; 326:2120. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34874431>
10. Kurani SS, Lampman MA, Funni SA *et al.* Association Between Area-Level Socioeconomic Deprivation and Diabetes Care Quality in US Primary Care Practices. JAMA network open 2021; 4:e2138438. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964856>
11. Abdel-Bakky MS, Alqasoumi A, Altowayan WM *et al.* Simvastatin mitigates streptozotocin-induced type 1 diabetes in mice through downregulation of ADAM10 and ADAM17. Life sciences 2022; 289:120224. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34896343>
12. Chang R, Liu SY, Zhao LM. Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021; 100:e27802. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964748>
13. Min HK, Kim SH, Choi JH *et al.* Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data. World journal of clinical cases 2021; 9:10198-10207. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34904090>

New Treatments

1. Furtado JD, Ruotolo G, Nicholls SJ *et al.* Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease. Arterioscler Thromb Vasc Biol 2022; 42:227-237. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34937388>
2. Caldara R, Maffi P, Costa S *et al.* COVID-19 in Solid Organ Transplant Recipient: Exploring Cumulative Incidence, Seroprevalence and Risk Factors for Disease Severity. Biology (Base) 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34943264>
3. Sammons E, Hopewell JC, Chen F *et al.* Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. Eur Heart J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34910136>
4. White HD, Schwartz GG, Szarek M *et al.* Alirocumab after acute coronary syndrome in patients with a history of heart failure. Eur Heart J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34922353>
5. Nelson AJ, Bubb K, Nicholls SJ. An update on emerging drugs for the treatment of hypercholesterolemia. Expert opinion on emerging drugs 2021; 26:363-369. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34842495>

6. Bardolia C, Amin NS, Turgeon J. Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol. Frontiers in cardiovascular medicine 2021; 8:789931. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34869702>
7. Gao J, Liu JY, Lu PJ *et al.* Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol. Front Physiol 2021; 12:750872. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34887772>
8. Aguilar-Salinas CA, Gómez-Díaz RA, Corral P. New Therapies for Primary Hyperlipidaemia. J Clin Endocrinol Metab 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34888679>
9. McKinley EC, Bittner VA, Brown TM *et al.* Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34848176>
10. Warden BA, Cardiology BA, Purnell JQ *et al.* Real-world utilization of bempedoic acid in an academic preventive cardiology practice. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34924351>
11. Levintow SN, Orroth KK, Breskin A *et al.* Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies. Pharmacoepidemiol Drug Saf 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34894377>

Other

1. Tully PJ, Ang SY, Lee EJ *et al.* Psychological and pharmacological interventions for depression in patients with coronary artery disease. The Cochrane database of systematic reviews 2021; 12:Cd008012. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34910821>
2. Gaitán-Duarte HG, Álvarez-Moreno C, Rincón-Rodríguez CJ *et al.* Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. EClinicalMedicine 2022; 43:101242. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957385>
3. Freire de Carvalho J, Brandão Neto R, Skare T. Thrombotic microangiopathy in primary antiphospholipid syndrome is linked to stroke and less deep venous thrombosis. Eur Rev Med Pharmacol Sci 2021; 25:7369-7374. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34919237>
4. Felici N, Liu D, Maret J *et al.* Long-Term Abnormalities of Lipid Profile After a Single Episode of Sepsis. Frontiers in cardiovascular medicine 2021; 8:674248. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34869619>
5. Yan J, Zheng K, Liu A, Cheng W. The Impact of Cognitive Function on the Effectiveness and Safety of Intensive Blood Pressure Control for Patients With Hypertension: A post-hoc Analysis of SPRINT. Frontiers in cardiovascular medicine 2021; 8:777250. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34901238>
6. Demasi M, DuBroff R. The Fallacy of OTC Statin Therapy. J Am Coll Cardiol 2021; 78:e325. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34915992>
7. Nissen SE. Reply: The Fallacy of OTC Statin Therapy. J Am Coll Cardiol 2021; 78:e327. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34915993>
8. Eid WE, Sapp EH, Wendt A *et al.* Improving Familial Hypercholesterolemia Diagnosis Using an EMR-based Hybrid Diagnostic Model. J Clin Endocrinol Metab 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34871430>
9. Qin M, Luo P, Wen X, Li J. Misdiagnosis of sitosterolemia in a patient as Evans syndrome and familial hypercholesterolemia. J Clin Lipidol 2021.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=34887220>
10. Vega GL, Wang J, Grundy SM. Prevalence and significance of risk enhancing biomarkers in the United States population at intermediate risk for atherosclerotic disease: Risk Enhancing Factors in Intermediate Risk for ASCVD. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34922882>
 11. Tsai CL, Chang YH, Su CH *et al.* Real-world data on the prescription of proprotein convertase subtilisin/kexin type 9 inhibitors in high-risk patients in a tertiary medical center. Journal of the Formosan Medical Association = Taiwan yi zhi 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34852937>
 12. Fedson DS. In-hospital statin treatment of COVID -19. The Journal of infectious diseases 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34897480>
 13. Mehrabi S, Torkan J, Hosseinzadeh M. Effect of atorvastatin on serum periostin and blood eosinophils in asthma - a placebo-controlled randomized clinical trial. J Int Med Res 2021; 49:3000605211063721. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34904467>
 14. Naville-Cook C, Rhea L, Triboletti M, White C. Analyzing the Clinical Outcomes of a Rapid Mass Conversion From Rosuvastatin to Atorvastatin in a VA Medical Center Outpatient Setting. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians 2017; 33:189-194. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34860938>
 15. Weissler EH, Jones WS. Who Will Own the Responsibility to Prescribe Statins? Tragedy of the Commons. JAMA network open 2021; 4:e2137605. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34860247>
 16. Avan R, Sahebnaasagh A, Hashemi J *et al.* Update on Statin Treatment in Patients with Neuropsychiatric Disorders. Life (Basel) 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34947895>
 17. Zhang L, Bao Y, Tao S *et al.* The association between cardiovascular drugs and depression/anxiety in patients with cardiovascular disease: A meta-analysis. Pharmacol Res 2022; 175:106024. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34890773>
 18. Hsieh K, Wang Y, Chen L *et al.* Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence. Scientific reports 2021; 11:23179. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34848761>
 19. Shen L, Qiu L, Wang L *et al.* Statin Use and In-hospital Mortality in Patients with COVID-19 and Coronary Heart Disease. Scientific reports 2021; 11:23874. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34903765>
 20. Globler N, Stewart L, Seo J *et al.* Incidence and characteristics of arterial thromboemboli in patients with COVID-19. Thromb J 2021; 19:104. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34930306>
 21. Mehta RM, Pandol SJ, Joshi PR. Idiopathic chronic pancreatitis: Beyond antioxidants. World J Gastroenterol 2021; 27:7423-7432. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34887640>

PAD and statins

1. Pañç C, Güler A, Gürbak İ *et al.* Association Between CRP/Albumin Ratio and Long-Term Mortality in Patients With cHronic Limb-Threatening Ischemia Undergoing EndovaScular Therapy Below The Knee: The ACHILES-BTK Registry. Annals of vascular surgery 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34896550>
2. Cai Y, Zhao F. Fluvastatin suppresses the proliferation, invasion, and migration and promotes the apoptosis of endometrial cancer cells by upregulating Sirtuin 6 (SIRT6).

Bioengineered 2021; 12:12509-12520. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34927546>

3. Erratum: High Apolipoprotein E Levels Predict Adverse Limb Events in Patients with Peripheral Artery Disease Due to Peripheral Artery Disease Undergoing Endovascular Treatment and On-Statins Treatment. Int Heart J 2021; 62:1445. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34853232>
4. Ramberg C, Hindberg K, Biedermann JS *et al.* Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial. Journal of thrombosis and haemostasis : JTH 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34953155>
5. Singh N, Ding L, Devera J *et al.* Prescribing of Statins After Lower Extremity Revascularization Procedures in the US. JAMA network open 2021; 4:e2136014. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34860245>
6. Mohapatra D, Das B, Suresh V *et al.* Correction to: Fluvastatin sensitizes pancreatic cancer cells toward radiation therapy and suppresses radiation- and/or TGF- β -induced tumor-associated fibrosis. Lab Invest 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34853441>

Pleiotropic effects of statins

1. Sambamoorthy U, Manjappa AS, Eswara BRM *et al.* Vitamin E Oil Incorporated Liposomal Melphalan and Simvastatin: Approach to Obtain Improved Physicochemical Characteristics of Hydrolysable Melphalan and Anticancer Activity in Combination with Simvastatin Against Multiple Myeloma. AAPS PharmSciTech 2021; 23:23. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34907484>
2. Yu Y, Zhang YH, Liu L *et al.* Bioinformatics analysis of candidate genes and potential therapeutic drugs targeting adipose tissue in obesity. Adipocyte 2022; 11:1-10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964707>
3. You HS, Shin SJ, Kim J, Kang HT. Statin Use and Incidence of Chronic Kidney Disease in Hypercholesterolemia Patients with Normal Renal Function. Am J Nephrol 2021; 52:940-948. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34864729>
4. Li Y, Chen S, Zhu J *et al.* Lovastatin enhances chemosensitivity of paclitaxel-resistant prostate cancer cells through inhibition of CYP2C8. Biochem Biophys Res Commun 2022; 589:85-91. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34896780>
5. Tian H, Qiang T, Wang J *et al.* Simvastatin regulates the proliferation, apoptosis, migration and invasion of human acute myeloid leukemia cells via miR-19a-3p/HIF-1 α axis. Bioengineered 2021; 12:11898-11908. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34895042>
6. Wesolowska A, Winiarska H, Owoc J *et al.* Effects of Low-Dose Atorvastatin on the Peripheral Blood Mononuclear Cell Secretion of Angiogenic Factors in Type 2 Diabetes. Biomolecules 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34944529>
7. Smith MC, Ashdown HF, Sheppard JP *et al.* Statin prescription in patients with chronic obstructive pulmonary disease and risk of exacerbations: a retrospective cohort study in the Clinical Practice Research Datalink. BMJ Open 2021; 11:e050757. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34876426>
8. Antonenko A, Leahy A, Babenko M, Lyons D. Low dose hydrophilic statins are the preferred agents for females at risk of osteoporosis. Bone Rep 2022; 16:101152. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34934779>
9. Elakkad YE, Mohamed SNS, Abuelezz NZ. Potentiating the Cytotoxic Activity of a Novel Simvastatin-Loaded Cubosome against Breast Cancer Cells: Insights on Dual

- Cell Death via Ferroptosis and Apoptosis. Breast cancer (Dove Medical Press) 2021; 13:675-689. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34934357>
10. Radyukhina NV, Ruleva NY, Filatova AY, Aref'eva TI. Inhibitors of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (Statins) Suppress Proliferation and Motility of Human CD4(+) T Lymphocytes in Culture. Bulletin of experimental biology and medicine 2021; 172:137-142. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34855095>
 11. Goldberg H, Mohsin FK, Chandrasekar T *et al.* The association of statin subgroups with lower urinary tract symptoms following a prostate biopsy. Can Urol Assoc J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34941486>
 12. Seo SI, Park CH, Kim TJ *et al.* Aspirin, metformin, and statin use on the risk of gastric cancer: A nationwide population-based cohort study in Korea with systematic review and meta-analysis. Cancer medicine 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970858>
 13. Ellimuttill TM, Harrison K, Rollins AT *et al.* Effect of Statin Intensity on the Progression of Cardiac Allograft Vasculopathy. Card Fail Rev 2021; 7:e15. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950505>
 14. Athyros VG, Katsiki N, Mikhailidis DP. Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis: RE: Fatima K, Moeed A, Waqar E, Atif AR, Kamran A, Rizvi H, Suri NF, Haider H, Shuja SH, Khalid M, Minhas AMK. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2021 Oct 1:101816. doi: 10.1016/j.clinre.2021.101816. Epub ahead of print. PMID:34607067. Clin Res Hepatol Gastroenterol 2021:101842. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34920141>
 15. Jakab J, Zjalic M, Mikšić Š *et al.* Effect of Metformin and Simvastatin in Inhibiting Proadipogenic Transcription Factors. Curr Issues Mol Biol 2021; 43:2082-2097. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34940118>
 16. Radbakhsh S, Kovanen PT, Sahebkar A. Regulating NETosis: An emerging facet of statin pleiotropy. Drug discovery today 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958959>
 17. Ding L, Chen Q, Chen K *et al.* Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation. Eur J Pharmacol 2021; 913:174633. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34843676>
 18. Park J, Kang H, Choi YS *et al.* Prevention of Intra-Abdominal Adhesions Using the Combination of Mediclore® and a Statin. Eur Surg Res 2021:1-9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34864732>
 19. Marchianò S, Biagioli M, Roselli R *et al.* Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2022; 36:e22060. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34862975>
 20. Zhang WT, Wang XJ, Xue CM *et al.* The Effect of Cardiovascular Medications on Disease-Related Outcomes in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Frontiers in pharmacology 2021; 12:771804. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34858190>
 21. Pose E, Solà E, Lozano JJ *et al.* Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. Hepatol Commun 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964311>
 22. Mottaghitlab F, Motasadizadeh H, Shokrgozar MA *et al.* Fabrication of Silk Scaffold Containing Simvastatin-Loaded Silk Fibroin Nanoparticles for Regenerating Bone

- Defects. Iranian biomedical journal 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34875820>
23. Akbarian R, Chamanara M, Rashidian A *et al.* Atorvastatin prevents the development of diabetic neuropathic nociception by possible involvement of nitrgergic system. J Appl Biomed 2021; 19:48-56. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34907715>
 24. Lee JS, Park SC, Kim SD. Effects of hypercholesterolemia on expansion of abdominal aortic aneurysm in rat model. Journal of cardiothoracic surgery 2021; 16:352. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961565>
 25. Chen PH, Jhou HJ, Chung CH *et al.* The Effect of Statins in Cancer Risk Reduction in Patients on Dialysis: A Population-Based Case-Control Study. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34884304>
 26. Mehrabi S, Torkan J, Hosseinzadeh M. Effect of atorvastatin on serum periostin and blood eosinophils in asthma - a placebo-controlled randomized clinical trial. J Int Med Res 2021; 49:3000605211063721. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34904467>
 27. Lewis MM, Albertson RM, Du G *et al.* Parkinson's Disease Progression and Statins: Hydrophobicity Matters. Journal of Parkinson's disease 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958045>
 28. De Giorgi R, Martens M, Rizzo Pesci N *et al.* The effects of atorvastatin on emotional processing, reward learning, verbal memory and inflammation in healthy volunteers: An experimental medicine study. Journal of psychopharmacology (Oxford, England) 2021; 35:1479-1487. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34872404>
 29. Ramberg C, Hindberg K, Biedermann JS *et al.* Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial. Journal of thrombosis and haemostasis : JTH 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34953155>
 30. Patnaik SK, Petrucci C, Barbi J *et al.* Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC. JTO Clin Res Rep 2021; 2:100254. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34877556>
 31. Mohapatra D, Das B, Suresh V *et al.* Correction to: Fluvastatin sensitizes pancreatic cancer cells toward radiation therapy and suppresses radiation- and/or TGF- β -induced tumor-associated fibrosis. Lab Invest 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34853441>
 32. Gouni S, Strati P, Toruner G *et al.* Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma. Leukemia & lymphoma 2021:1-12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969327>
 33. Avan R, Sahebnaasagh A, Hashemi J *et al.* Update on Statin Treatment in Patients with Neuropsychiatric Disorders. Life (Basel) 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34947895>
 34. Abdel-Bakky MS, Alqasoumi A, Altowayan WM *et al.* Simvastatin mitigates streptozotocin-induced type 1 diabetes in mice through downregulation of ADAM10 and ADAM17. Life sciences 2022; 289:120224. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34896343>
 35. Wu L, Cheng Y, Peng S *et al.* Sphingosine Kinase 1 Plays an Important Role in Atorvastatin-Mediated Anti-Inflammatory Effect against Acute Lung Injury. Mediators Inflamm 2021; 2021:9247285. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970075>
 36. Heidari B, Babaei M, Yosefghahri B. Prevention of Osteoarthritis Progression by Statins, Targeting Metabolic and Inflammatory Aspects: A Review. Mediterr J Rheumatol 2021; 32:227-236. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964026>
 37. Lee WM, Bae JH, Chang Y *et al.* Effect of Nutrition Education in NAFLD Patients Undergoing Simultaneous Hyperlipidemia Pharmacotherapy: A Randomized

- Controlled Trial. Nutrients 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960005>
38. Bourguillon RO, Stokes WA, Dorth J, Schmitt NC. Repurposing Statin Drugs to Decrease Toxicity and Improve Survival Outcomes in Head and Neck Cancer. OTO Open 2021; 5:2473974x211065715. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34917872>
39. Du L, Jia JH, Xue WY, Qi JC. Effect of tadalafil combined with atorvastatin on hemodynamics and sexual function in middle-aged and elderly patients with hyperlipidemia complicated with erectile dysfunction. Pak J Med Sci 2021; 37:1965-1971. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34912427>
40. Sun Y, Yuan L, Liu X *et al.* Effects of atorvastatin and Zishen Qingqi granules on immune function and liver function of patients with systemic lupus erythematosus with mild and moderate activity. Pak J Pharm Sci 2021; 34:2085-2090. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34862878>
41. Grabarek BO, Boroń D, Morawiec E *et al.* Crosstalk between Statins and Cancer Prevention and Therapy: An Update. Pharmaceuticals (Basel, Switzerland) 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959621>
42. Kwon MJ, Kang HS, Kim JH *et al.* Association between Statin Use and Gastric Cancer: A Nested Case-Control Study Using a National Health Screening Cohort in Korea. Pharmaceuticals (Basel, Switzerland) 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959682>
43. Evans MD, McDowell SA. Pleiotropic Effects of Statins: New Therapeutic Approaches to Chronic, Recurrent Infection by *Staphylococcus aureus*. Pharmaceutics 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959329>
44. Zhang L, Bao Y, Tao S *et al.* The association between cardiovascular drugs and depression/anxiety in patients with cardiovascular disease: A meta-analysis. Pharmacol Res 2022; 175:106024. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34890773>
45. Matei SC, Matei M, Anghel FM *et al.* Impact of statin treatment on patients diagnosed with chronic venous disease. Morphological analysis of the venous wall and clinical implications. Phlebology 2021:2683555211053566. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34877912>
46. Stupica D, Bajrović FF, Blagus R *et al.* Association between statin use and clinical course, microbiologic characteristics, and long-term outcome of early Lyme borreliosis. A post hoc analysis of prospective clinical trials of adult patients with erythema migrans. PLoS One 2021; 16:e0261194. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34914751>
47. Nakayama H, Sekine Y, Oka D *et al.* Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer. Prostate 2022; 82:314-322. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34843630>
48. Postolache TT, Medoff DR, Brown CH *et al.* Lipophilic vs. hydrophilic statins and psychiatric hospitalizations and emergency room visits in US Veterans with schizophrenia and bipolar disorder. Pteridines 2021; 32:48-69. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34887622>
49. Chen J, Huang C, Zhang T *et al.* The effects of statins on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive biology and endocrinology : RB&E 2021; 19:189. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34930305>
50. Vigneau AL, Rico C, Boerboom D, Paquet M. Statins downregulate YAP and TAZ and exert anti-cancer effects in canine mammary tumour cells. Vet Comp Oncol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34881506>
51. Mehta RM, Pandol SJ, Joshi PR. Idiopathic chronic pancreatitis: Beyond antioxidants. World J Gastroenterol 2021; 27:7423-7432.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=34887640>

52. Jull A, Lu H, Jiang Y. Statins and venous leg ulcer healing: Secondary analysis of data from a cohort of three randomised controlled trials. Wound repair and regeneration : official publication of the Wound Healing Society (and) the European Tissue Repair Society 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34894034>

Primary Prevention

1. Bergami M, Cenko E, Yoon J *et al*. Statins for primary prevention among elderly men and women. Cardiovascular research 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34864917>
2. Volpe M, Patrono C. The cardiovascular benefits of statins outweigh adverse effects in primary prevention: results of a large systematic review and meta-analysis. Eur Heart J 2021; 42:4518-4519. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34849717>
3. Cainzos-Achirica M, Quispe R, Dudum R *et al*. CAC for Risk Stratification Among Individuals With Hypertriglyceridemia Free of Clinical Atherosclerotic Cardiovascular Disease. JACC. Cardiovascular imaging 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34922873>
4. Muhlestein JB, Knowlton KU, Le VT *et al*. Coronary Artery Calcium Versus Pooled Cohort Equations Score for Primary Prevention Guidance: Randomized Feasibility Trial. JACC. Cardiovascular imaging 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34922872>
5. Weng SF, Akyea RK, Man KK *et al*. Determining propensity for sub-optimal low-density lipoprotein cholesterol response to statins and future risk of cardiovascular disease. PLoS One 2021; 16:e0260839. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34855879>
6. Siostrzonek P, Brath H, Zweiker R *et al*. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study. Wien Klin Wochenschr 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34870742>

Registry data

1. You HS, Shin SJ, Kim J, Kang HT. Statin Use and Incidence of Chronic Kidney Disease in Hypercholesterolemia Patients with Normal Renal Function. Am J Nephrol 2021; 52:940-948. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34864729>
2. Mortensen MB, Nordestgaard BG. Guidelines versus trial-evidence for statin use in primary prevention: The Copenhagen General Population Study. Atherosclerosis 2022; 341:20-26. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959205>
3. Smith MC, Ashdown HF, Sheppard JP *et al*. Statin prescription in patients with chronic obstructive pulmonary disease and risk of exacerbations: a retrospective cohort study in the Clinical Practice Research Datalink. BMJ Open 2021; 11:e050757. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34876426>
4. Seo SI, Park CH, Kim TJ *et al*. Aspirin, metformin, and statin use on the risk of gastric cancer: A nationwide population-based cohort study in Korea with systematic review and meta-analysis. Cancer medicine 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970858>
5. Adams A, Bojara W, Romanens M. Effect of Statin Treatment in Patients With Advanced Carotid Atherosclerosis: An Observational Outcome Study. Cardiology research 2021; 12:335-339. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970362>

6. Al Rifai M, Blaha MJ, Nambi V *et al.* Determinants of Incident Atherosclerotic Cardiovascular Disease Events Among Those With Absent Coronary Artery Calcium: Multi-Ethnic Study of Atherosclerosis. Circulation 2022; 145:259-267. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34879218>
7. Butalia S, Chen G, Duan Q, Anderson TJ. Care gaps in achieving cholesterol targets in people with diabetes: a population-based study in a universal health care setting. Diabetes Res Clin Pract 2021;109177. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34923023>
8. Shrauner W, Lord EM, Nguyen XT *et al.* Frailty and cardiovascular mortality in more than 3 million US Veterans. Eur Heart J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34907422>
9. McKinley EC, Bittner VA, Brown TM *et al.* Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34848176>
10. Vega GL, Wang J, Grundy SM. Prevalence and significance of risk enhancing biomarkers in the United States population at intermediate risk for atherosclerotic disease: Risk Enhancing Factors in Intermediate Risk for ASCVD. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34922882>
11. Chen PH, Jhou HJ, Chung CH *et al.* The Effect of Statins in Cancer Risk Reduction in Patients on Dialysis: A Population-Based Case-Control Study. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34884304>
12. Chang JC, Chen YJ, Chen IC *et al.* Perinatal Outcomes After Statin Exposure During Pregnancy. JAMA network open 2021; 4:e2141321. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967881>
13. Singh N, Ding L, Devera J *et al.* Prescribing of Statins After Lower Extremity Revascularization Procedures in the US. JAMA network open 2021; 4:e2136014. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34860245>
14. Thompson W, Morin L, Jarbøl DE *et al.* Statin Discontinuation and Cardiovascular Events Among Older People in Denmark. JAMA network open 2021; 4:e2136802. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34854906>
15. Bannay A, Bories M, Le Corre P *et al.* Leveraging National Claims and Hospital Big Data: Cohort Study on a Statin-Drug Interaction Use Case. JMIR Med Inform 2021; 9:e29286. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34898457>
16. Patnaik SK, Petrucci C, Barbi J *et al.* Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC. JTO Clin Res Rep 2021; 2:100254. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34877556>
17. Kwon MJ, Kang HS, Kim JH *et al.* Association between Statin Use and Gastric Cancer: A Nested Case-Control Study Using a National Health Screening Cohort in Korea. Pharmaceuticals (Basel, Switzerland) 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959682>
18. Stupica D, Bajrović FF, Blagus R *et al.* Association between statin use and clinical course, microbiologic characteristics, and long-term outcome of early Lyme borreliosis. A post hoc analysis of prospective clinical trials of adult patients with erythema migrans. PLoS One 2021; 16:e0261194. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34914751>
19. Postolache TT, Medoff DR, Brown CH *et al.* Lipophilic vs. hydrophilic statins and psychiatric hospitalizations and emergency room visits in US Veterans with schizophrenia and bipolar disorder. Pteridines 2021; 32:48-69. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34887622>
20. Shen L, Qiu L, Wang L *et al.* Statin Use and In-hospital Mortality in Patients with COVID-19 and Coronary Heart Disease. Scientific reports 2021; 11:23874.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=34903765>

21. Min HK, Kim SH, Choi JH *et al.* Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data. World journal of clinical cases 2021; 9:10198-10207. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34904090>

Renal Disease

1. You HS, Shin SJ, Kim J, Kang HT. Statin Use and Incidence of Chronic Kidney Disease in Hypercholesterolemia Patients with Normal Renal Function. Am J Nephrol 2021; 52:940-948. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34864729>
2. Lv J, Ren C, Hu Q. Effect of statins on the treatment of early diabetic nephropathy: a systematic review and meta-analysis of nine randomized controlled trials. Ann Palliat Med 2021; 10:11548-11557. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34872280>
3. Bermudez-Lopez M, Perpiñan H, Amigo N *et al.* Advanced lipoprotein parameters could better explain atheromatosis in non-diabetic chronic kidney disease patients. Clinical kidney journal 2021; 14:2591-2599. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950470>
4. Kraler S, Blaser MC, Aikawa E *et al.* Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy. Eur Heart J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34849696>
5. Thongnak L, Pengrattanachot N, Promsan S *et al.* The combination of dapagliflozin and statins ameliorates renal injury through attenuating the activation of inflammasome-mediated autophagy in insulin-resistant rats. Journal of biochemical and molecular toxicology 2021:e22978. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34939712>
6. Chen PH, Jhou HJ, Chung CH *et al.* The Effect of Statins in Cancer Risk Reduction in Patients on Dialysis: A Population-Based Case-Control Study. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34884304>
7. Lee C, Park JT, Chang TI *et al.* Low-density lipoprotein cholesterol levels and adverse clinical outcomes in chronic kidney disease: Results from the KNOW-CKD. Nutrition, metabolism, and cardiovascular diseases : NMCD 2022; 32:410-419. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34893405>

Reviews

1. Wan S, Ding Y, Ji X, Meng R. The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases. Aging and disease 2021; 12:1857-1871. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34881073>
2. Wylie LE, Waterbrook AL, Dalen JE. Are Statins Indicated in Senior Citizens? A Review of Statin Therapy in the Elderly. Am J Med 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34856186>
3. Shehryar M, Ashraf MF, Uzair Ahmad R *et al.* Statin-Induced Thrombocytopenia in a Young Female: A Case Report and Literature Review. Cureus 2021; 13:e19436. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34909340>
4. Satny M, Hubacek JA, Vrablik M. Statins and Inflammation. Curr Atheroscler Rep 2021; 23:80. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34851454>
5. Radbakhsh S, Kovanen PT, Sahebkar A. Regulating NETosis: An emerging facet of statin pleiotropy. Drug discovery today 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958959>

6. Laufs U, Weingärtner O, Kassner U, Schatz U. (State of the Art: Statin Therapy). Deutsche medizinische Wochenschrift (1946) 2022; 147:62-68. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34872149>
7. Nelson AJ, Bubb K, Nicholls SJ. An update on emerging drugs for the treatment of hypercholesterolemia. Expert opinion on emerging drugs 2021; 26:363-369. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34842495>
8. van der Laarse A, Cobbaert CM. Biochemical risk factors of atherosclerotic cardiovascular disease: from a narrow and controversial approach to an integral approach and precision medicine. Expert Rev Cardiovasc Ther 2021; 19:1085-1096. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34937476>
9. Bardolia C, Amin NS, Turgeon J. Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol. Frontiers in cardiovascular medicine 2021; 8:789931. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34869702>
10. Beltrán Romero LM, Vallejo-Vaz AJ, Muñoz Grijalvo O. Cerebrovascular Disease and Statins. Frontiers in cardiovascular medicine 2021; 8:778740. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34926626>
11. Cobos-Palacios L, Sanz-Cánovas J, Muñoz-Ubeda M *et al.* Statin Therapy in Very Old Patients: Lights and Shadows. Frontiers in cardiovascular medicine 2021; 8:779044. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34912868>
12. Ábrego-Gacía A, Poggi-Varaldo HM, Robles-González V *et al.* Lovastatin as a supplement to mitigate rumen methanogenesis: an overview. J Anim Sci Biotechnol 2021; 12:123. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34911584>
13. McKinley EC, Bittner VA, Brown TM *et al.* Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34848176>
14. Warden BA, Cardiology BA, Purnell JQ *et al.* Real-world utilization of bempedoic acid in an academic preventive cardiology practice. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34924351>
15. Heidari B, Babaei M, Yosefghahri B. Prevention of Osteoarthritis Progression by Statins, Targeting Metabolic and Inflammatory Aspects: A Review. Mediterr J Rheumatol 2021; 32:227-236. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964026>
16. Bourguillon RO, Stokes WA, Dorth J, Schmitt NC. Repurposing Statin Drugs to Decrease Toxicity and Improve Survival Outcomes in Head and Neck Cancer. OTO Open 2021; 5:2473974x211065715. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34917872>
17. Grabarek BO, Boroń D, Morawiec E *et al.* Crosstalk between Statins and Cancer Prevention and Therapy: An Update. Pharmaceuticals (Basel, Switzerland) 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959621>
18. Gnanenthiran SR, Agarwal A, Patel A. Frontiers of cardiovascular polypills: From atherosclerosis and beyond. Trends Cardiovasc Med 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973412>
19. Guo YF. (Improving the prevention and treatment of cardiovascular disease through strictly controlling the risk factors: interpretation of the 2021 ESC clinical practice guide for cardiovascular disease prevention). Zhonghua xin xue guan bing za zhi 2021; 49:1244-1246. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34905905>

Pleiotropic effects of statins

1. Sambamoorthy U, Manjappa AS, Eswara BRM *et al.* Vitamin E Oil Incorporated Liposomal Melphalan and Simvastatin: Approach to Obtain Improved Physicochemical Characteristics of Hydrolysable Melphalan and Anticancer Activity

- in Combination with Simvastatin Against Multiple Myeloma. AAPS PharmSciTech 2021; 23:23. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34907484>
2. Yu Y, Zhang YH, Liu L *et al.* Bioinformatics analysis of candidate genes and potential therapeutic drugs targeting adipose tissue in obesity. Adipocyte 2022; 11:1-10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964707>
 3. You HS, Shin SJ, Kim J, Kang HT. Statin Use and Incidence of Chronic Kidney Disease in Hypercholesterolemia Patients with Normal Renal Function. Am J Nephrol 2021; 52:940-948. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34864729>
 4. Li Y, Chen S, Zhu J *et al.* Lovastatin enhances chemosensitivity of paclitaxel-resistant prostate cancer cells through inhibition of CYP2C8. Biochem Biophys Res Commun 2022; 589:85-91. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34896780>
 5. Tian H, Qiang T, Wang J *et al.* Simvastatin regulates the proliferation, apoptosis, migration and invasion of human acute myeloid leukemia cells via miR-19a-3p/HIF-1 α axis. Bioengineered 2021; 12:11898-11908. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34895042>
 6. Wesołowska A, Winiarska H, Owoc J *et al.* Effects of Low-Dose Atorvastatin on the Peripheral Blood Mononuclear Cell Secretion of Angiogenic Factors in Type 2 Diabetes. Biomolecules 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34944529>
 7. Smith MC, Ashdown HF, Sheppard JP *et al.* Statin prescription in patients with chronic obstructive pulmonary disease and risk of exacerbations: a retrospective cohort study in the Clinical Practice Research Datalink. BMJ Open 2021; 11:e050757. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34876426>
 8. Antonenko A, Leahy A, Babenko M, Lyons D. Low dose hydrophilic statins are the preferred agents for females at risk of osteoporosis. Bone Rep 2022; 16:101152. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34934779>
 9. Elakkad YE, Mohamed SNS, Abuelezz NZ. Potentiating the Cytotoxic Activity of a Novel Simvastatin-Loaded Cubosome against Breast Cancer Cells: Insights on Dual Cell Death via Ferroptosis and Apoptosis. Breast cancer (Dove Medical Press) 2021; 13:675-689. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34934357>
 10. Radyukhina NV, Ruleva NY, Filatova AY, Aref'eva TI. Inhibitors of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (Statins) Suppress Proliferation and Motility of Human CD4(+) T Lymphocytes in Culture. Bulletin of experimental biology and medicine 2021; 172:137-142. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34855095>
 11. Goldberg H, Mohsin FK, Chandrasekar T *et al.* The association of statin subgroups with lower urinary tract symptoms following a prostate biopsy. Can Urol Assoc J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34941486>
 12. Seo SI, Park CH, Kim TJ *et al.* Aspirin, metformin, and statin use on the risk of gastric cancer: A nationwide population-based cohort study in Korea with systematic review and meta-analysis. Cancer medicine 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970858>
 13. Ellimuttill TM, Harrison K, Rollins AT *et al.* Effect of Statin Intensity on the Progression of Cardiac Allograft Vasculopathy. Card Fail Rev 2021; 7:e15. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950505>
 14. Athyros VG, Katsiki N, Mikhailidis DP. Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis: RE: Fatima K, Moeed A, Waqar E, Atif AR, Kamran A, Rizvi H, Suri NF, Haider H, Shuja SH, Khalid M, Minhas AMK. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2021 Oct 1:101816. doi: 10.1016/j.clinre.2021.101816. Epub ahead of print. PMID:34607067. Clin Res Hepatol Gastroenterol 2021:101842. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34920141>

15. Jakab J, Zjalic M, Mikšić Š *et al.* Effect of Metformin and Simvastatin in Inhibiting Proadipogenic Transcription Factors. Curr Issues Mol Biol 2021; 43:2082-2097. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34940118>
16. Radbakhsh S, Kovanen PT, Sahebkar A. Regulating NETosis: An emerging facet of statin pleiotropy. Drug discovery today 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958959>
17. Ding L, Chen Q, Chen K *et al.* Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation. Eur J Pharmacol 2021; 913:174633. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34843676>
18. Park J, Kang H, Choi YS *et al.* Prevention of Intra-Abdominal Adhesions Using the Combination of Mediclore® and a Statin. Eur Surg Res 2021:1-9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34864732>
19. Marchianò S, Biagioli M, Roselli R *et al.* Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2022; 36:e22060. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34862975>
20. Zhang WT, Wang XJ, Xue CM *et al.* The Effect of Cardiovascular Medications on Disease-Related Outcomes in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Frontiers in pharmacology 2021; 12:771804. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34858190>
21. Pose E, Solà E, Lozano JJ *et al.* Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. HepatoL Commun 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964311>
22. Mottaghitalab F, Motasadizadeh H, Shokrgozar MA *et al.* Fabrication of Silk Scaffold Containing Simvastatin-Loaded Silk Fibroin Nanoparticles for Regenerating Bone Defects. Iranian biomedical journal 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34875820>
23. Akbarian R, Chamanara M, Rashidian A *et al.* Atorvastatin prevents the development of diabetic neuropathic nociception by possible involvement of nitrgergic system. J Appl Biomed 2021; 19:48-56. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34907715>
24. Lee JS, Park SC, Kim SD. Effects of hypercholesterolemia on expansion of abdominal aortic aneurysm in rat model. Journal of cardiothoracic surgery 2021; 16:352. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34961565>
25. Chen PH, Jhou HJ, Chung CH *et al.* The Effect of Statins in Cancer Risk Reduction in Patients on Dialysis: A Population-Based Case-Control Study. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34884304>
26. Mehrabi S, Torkan J, Hosseinzadeh M. Effect of atorvastatin on serum periostin and blood eosinophils in asthma - a placebo-controlled randomized clinical trial. J Int Med Res 2021; 49:3000605211063721. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34904467>
27. Lewis MM, Albertson RM, Du G *et al.* Parkinson's Disease Progression and Statins: Hydrophobicity Matters. Journal of Parkinson's disease 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958045>
28. De Giorgi R, Martens M, Rizzo Pesci N *et al.* The effects of atorvastatin on emotional processing, reward learning, verbal memory and inflammation in healthy volunteers: An experimental medicine study. Journal of psychopharmacology (Oxford, England) 2021; 35:1479-1487. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34872404>
29. Ramberg C, Hindberg K, Biedermann JS *et al.* Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial.

Journal of thrombosis and haemostasis : JTH 2021.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=34953155>

30. Patnaik SK, Petrucci C, Barbi J *et al.* Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC. JTO Clin Res Rep 2021; 2:100254. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34877556>
31. Mohapatra D, Das B, Suresh V *et al.* Correction to: Fluvastatin sensitizes pancreatic cancer cells toward radiation therapy and suppresses radiation- and/or TGF- β -induced tumor-associated fibrosis. Lab Invest 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34853441>
32. Gouni S, Strati P, Toruner G *et al.* Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma. Leukemia & lymphoma 2021:1-12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34969327>
33. Avan R, Sahebnasagh A, Hashemi J *et al.* Update on Statin Treatment in Patients with Neuropsychiatric Disorders. Life (Basel) 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34947895>
34. Abdel-Bakky MS, Alqasoumi A, Altowayan WM *et al.* Simvastatin mitigates streptozotocin-induced type 1 diabetes in mice through downregulation of ADAM10 and ADAM17. Life sciences 2022; 289:120224. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34896343>
35. Wu L, Cheng Y, Peng S *et al.* Sphingosine Kinase 1 Plays an Important Role in Atorvastatin-Mediated Anti-Inflammatory Effect against Acute Lung Injury. Mediators Inflamm 2021; 2021:9247285. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970075>
36. Heidari B, Babaei M, Yosefghahri B. Prevention of Osteoarthritis Progression by Statins, Targeting Metabolic and Inflammatory Aspects: A Review. Mediterr J Rheumatol 2021; 32:227-236. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964026>
37. Lee WM, Bae JH, Chang Y *et al.* Effect of Nutrition Education in NAFLD Patients Undergoing Simultaneous Hyperlipidemia Pharmacotherapy: A Randomized Controlled Trial. Nutrients 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960005>
38. Bourguillon RO, Stokes WA, Dorth J, Schmitt NC. Repurposing Statin Drugs to Decrease Toxicity and Improve Survival Outcomes in Head and Neck Cancer. OTO Open 2021; 5:2473974x211065715. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34917872>
39. Du L, Jia JH, Xue WY, Qi JC. Effect of tadalafil combined with atorvastatin on hemodynamics and sexual function in middle-aged and elderly patients with hyperlipidemia complicated with erectile dysfunction. Pak J Med Sci 2021; 37:1965-1971. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34912427>
40. Sun Y, Yuan L, Liu X *et al.* Effects of atorvastatin and Zishen Qingqi granules on immune function and liver function of patients with systemic lupus erythematosus with mild and moderate activity. Pak J Pharm Sci 2021; 34:2085-2090. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34862878>
41. Grabarek BO, Boroń D, Morawiec E *et al.* Crosstalk between Statins and Cancer Prevention and Therapy: An Update. Pharmaceuticals (Basel, Switzerland) 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959621>
42. Kwon MJ, Kang HS, Kim JH *et al.* Association between Statin Use and Gastric Cancer: A Nested Case-Control Study Using a National Health Screening Cohort in Korea. Pharmaceuticals (Basel, Switzerland) 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959682>
43. Evans MD, McDowell SA. Pleiotropic Effects of Statins: New Therapeutic Approaches to Chronic, Recurrent Infection by *Staphylococcus aureus*. Pharmaceutics 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959329>

44. Zhang L, Bao Y, Tao S *et al.* The association between cardiovascular drugs and depression/anxiety in patients with cardiovascular disease: A meta-analysis. Pharmacol Res 2022; 175:106024. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34890773>
45. Matei SC, Matei M, Anghel FM *et al.* Impact of statin treatment on patients diagnosed with chronic venous disease. Morphological analysis of the venous wall and clinical implications. Phlebology 2021;2683555211053566. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34877912>
46. Stupica D, Bajrović FF, Blagus R *et al.* Association between statin use and clinical course, microbiologic characteristics, and long-term outcome of early Lyme borreliosis. A post hoc analysis of prospective clinical trials of adult patients with erythema migrans. PLoS One 2021; 16:e0261194. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34914751>
47. Nakayama H, Sekine Y, Oka D *et al.* Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer. Prostate 2022; 82:314-322. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34843630>
48. Postolache TT, Medoff DR, Brown CH *et al.* Lipophilic vs. hydrophilic statins and psychiatric hospitalizations and emergency room visits in US Veterans with schizophrenia and bipolar disorder. Pteridines 2021; 32:48-69. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34887622>
49. Chen J, Huang C, Zhang T *et al.* The effects of statins on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive biology and endocrinology : RB&E 2021; 19:189. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34930305>
50. Vigneau AL, Rico C, Boerboom D, Paquet M. Statins downregulate YAP and TAZ and exert anti-cancer effects in canine mammary tumour cells. Vet Comp Oncol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34881506>
51. Mehta RM, Pandol SJ, Joshi PR. Idiopathic chronic pancreatitis: Beyond antioxidants. World J Gastroenterol 2021; 27:7423-7432. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34887640>
52. Jull A, Lu H, Jiang Y. Statins and venous leg ulcer healing: Secondary analysis of data from a cohort of three randomised controlled trials. Wound repair and regeneration : official publication of the Wound Healing Society (and) the European Tissue Repair Society 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34894034>

Primary Prevention

1. Bergami M, Cenko E, Yoon J *et al.* Statins for primary prevention among elderly men and women. Cardiovascular research 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34864917>
2. Volpe M, Patrono C. The cardiovascular benefits of statins outweigh adverse effects in primary prevention: results of a large systematic review and meta-analysis. Eur Heart J 2021; 42:4518-4519. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34849717>
3. Cainzos-Achirica M, Quispe R, Dudum R *et al.* CAC for Risk Stratification Among Individuals With Hypertriglyceridemia Free of Clinical Atherosclerotic Cardiovascular Disease. JACC. Cardiovascular imaging 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34922873>
4. Muhlestein JB, Knowlton KU, Le VT *et al.* Coronary Artery Calcium Versus Pooled Cohort Equations Score for Primary Prevention Guidance: Randomized Feasibility Trial. JACC. Cardiovascular imaging 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34922872>

5. Weng SF, Akyea RK, Man KK *et al.* Determining propensity for sub-optimal low-density lipoprotein cholesterol response to statins and future risk of cardiovascular disease. PLoS One 2021; 16:e0260839. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34855879>
6. Siostrzonek P, Brath H, Zweiker R *et al.* Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study. Wien Klin Wochenschr 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34870742>

Registry data

1. You HS, Shin SJ, Kim J, Kang HT. Statin Use and Incidence of Chronic Kidney Disease in Hypercholesterolemia Patients with Normal Renal Function. Am J Nephrol 2021; 52:940-948. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34864729>
2. Mortensen MB, Nordestgaard BG. Guidelines versus trial-evidence for statin use in primary prevention: The Copenhagen General Population Study. Atherosclerosis 2022; 341:20-26. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959205>
3. Smith MC, Ashdown HF, Sheppard JP *et al.* Statin prescription in patients with chronic obstructive pulmonary disease and risk of exacerbations: a retrospective cohort study in the Clinical Practice Research Datalink. BMJ Open 2021; 11:e050757. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34876426>
4. Seo SI, Park CH, Kim TJ *et al.* Aspirin, metformin, and statin use on the risk of gastric cancer: A nationwide population-based cohort study in Korea with systematic review and meta-analysis. Cancer medicine 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970858>
5. Adams A, Bojara W, Romanens M. Effect of Statin Treatment in Patients With Advanced Carotid Atherosclerosis: An Observational Outcome Study. Cardiology research 2021; 12:335-339. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970362>
6. Al Rifai M, Blaha MJ, Nambi V *et al.* Determinants of Incident Atherosclerotic Cardiovascular Disease Events Among Those With Absent Coronary Artery Calcium: Multi-Ethnic Study of Atherosclerosis. Circulation 2022; 145:259-267. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34879218>
7. Butalia S, Chen G, Duan Q, Anderson TJ. Care gaps in achieving cholesterol targets in people with diabetes: a population-based study in a universal health care setting. Diabetes Res Clin Pract 2021:109177. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34923023>
8. Shrauner W, Lord EM, Nguyen XT *et al.* Frailty and cardiovascular mortality in more than 3 million US Veterans. Eur Heart J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34907422>
9. McKinley EC, Bittner VA, Brown TM *et al.* Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34848176>
10. Vega GL, Wang J, Grundy SM. Prevalence and significance of risk enhancing biomarkers in the United States population at intermediate risk for atherosclerotic disease: Risk Enhancing Factors in Intermediate Risk for ASCVD. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34922882>
11. Chen PH, Jhou HJ, Chung CH *et al.* The Effect of Statins in Cancer Risk Reduction in Patients on Dialysis: A Population-Based Case-Control Study. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34884304>
12. Chang JC, Chen YJ, Chen IC *et al.* Perinatal Outcomes After Statin Exposure During Pregnancy. JAMA network open 2021; 4:e2141321.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967881>
13. Singh N, Ding L, Devera J *et al.* Prescribing of Statins After Lower Extremity Revascularization Procedures in the US. JAMA network open 2021; 4:e2136014. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34860245>
 14. Thompson W, Morin L, Jarbøl DE *et al.* Statin Discontinuation and Cardiovascular Events Among Older People in Denmark. JAMA network open 2021; 4:e2136802. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34854906>
 15. Bannay A, Bories M, Le Corre P *et al.* Leveraging National Claims and Hospital Big Data: Cohort Study on a Statin-Drug Interaction Use Case. JMIR Med Inform 2021; 9:e29286. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34898457>
 16. Patnaik SK, Petrucci C, Barbi J *et al.* Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC. JTO Clin Res Rep 2021; 2:100254. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34877556>
 17. Kwon MJ, Kang HS, Kim JH *et al.* Association between Statin Use and Gastric Cancer: A Nested Case-Control Study Using a National Health Screening Cohort in Korea. Pharmaceuticals (Basel, Switzerland) 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959682>
 18. Stupica D, Bajrović FF, Blagus R *et al.* Association between statin use and clinical course, microbiologic characteristics, and long-term outcome of early Lyme borreliosis. A post hoc analysis of prospective clinical trials of adult patients with erythema migrans. PLoS One 2021; 16:e0261194. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34914751>
 19. Postolache TT, Medoff DR, Brown CH *et al.* Lipophilic vs. hydrophilic statins and psychiatric hospitalizations and emergency room visits in US Veterans with schizophrenia and bipolar disorder. Pteridines 2021; 32:48-69. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34887622>
 20. Shen L, Qiu L, Wang L *et al.* Statin Use and In-hospital Mortality in Patients with COVID-19 and Coronary Heart Disease. Scientific reports 2021; 11:23874. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34903765>
 21. Min HK, Kim SH, Choi JH *et al.* Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data. World journal of clinical cases 2021; 9:10198-10207. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34904090>

Renal Disease

1. You HS, Shin SJ, Kim J, Kang HT. Statin Use and Incidence of Chronic Kidney Disease in Hypercholesterolemia Patients with Normal Renal Function. Am J Nephrol 2021; 52:940-948. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34864729>
2. Lv J, Ren C, Hu Q. Effect of statins on the treatment of early diabetic nephropathy: a systematic review and meta-analysis of nine randomized controlled trials. Ann Palliat Med 2021; 10:11548-11557. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34872280>
3. Bermudez-Lopez M, Perpiñan H, Amigo N *et al.* Advanced lipoprotein parameters could better explain atheromatosis in non-diabetic chronic kidney disease patients. Clinical kidney journal 2021; 14:2591-2599. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950470>
4. Kraler S, Blaser MC, Aikawa E *et al.* Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy. Eur Heart J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34849696>
5. Thongnak L, Pengrattanachot N, Promsan S *et al.* The combination of dapagliflozin and statins ameliorates renal injury through attenuating the activation of

inflammasome-mediated autophagy in insulin-resistant rats. Journal of biochemical and molecular toxicology 2021:e22978. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34939712>

6. Chen PH, Jhou HJ, Chung CH *et al.* The Effect of Statins in Cancer Risk Reduction in Patients on Dialysis: A Population-Based Case-Control Study. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34884304>
7. Lee C, Park JT, Chang TI *et al.* Low-density lipoprotein cholesterol levels and adverse clinical outcomes in chronic kidney disease: Results from the KNOW-CKD. Nutrition, metabolism, and cardiovascular diseases : NMCD 2022; 32:410-419. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34893405>

Reviews

1. Wan S, Ding Y, Ji X, Meng R. The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases. Aging and disease 2021; 12:1857-1871. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34881073>
2. Wylie LE, Waterbrook AL, Dalen JE. Are Statins Indicated in Senior Citizens? A Review of Statin Therapy in the Elderly. Am J Med 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34856186>
3. Shehryar M, Ashraf MF, Uzair Ahmad R *et al.* Statin-Induced Thrombocytopenia in a Young Female: A Case Report and Literature Review. Cureus 2021; 13:e19436. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34909340>
4. Satny M, Hubacek JA, Vrablik M. Statins and Inflammation. Curr Atheroscler Rep 2021; 23:80. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34851454>
5. Radbakhsh S, Kovanen PT, Sahebkar A. Regulating NETosis: An emerging facet of statin pleiotropy. Drug discovery today 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958959>
6. Laufs U, Weingärtner O, Kassner U, Schatz U. (State of the Art: Statin Therapy). Deutsche medizinische Wochenschrift (1946) 2022; 147:62-68. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34872149>
7. Nelson AJ, Bubb K, Nicholls SJ. An update on emerging drugs for the treatment of hypercholesterolemia. Expert opinion on emerging drugs 2021; 26:363-369. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34842495>
8. van der Laarse A, Cobbaert CM. Biochemical risk factors of atherosclerotic cardiovascular disease: from a narrow and controversial approach to an integral approach and precision medicine. Expert Rev Cardiovasc Ther 2021; 19:1085-1096. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34937476>
9. Bardolia C, Amin NS, Turgeon J. Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol. Frontiers in cardiovascular medicine 2021; 8:789931. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34869702>
10. Beltrán Romero LM, Vallejo-Vaz AJ, Muñoz Grijalvo O. Cerebrovascular Disease and Statins. Frontiers in cardiovascular medicine 2021; 8:778740. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34926626>
11. Cobos-Palacios L, Sanz-Cánovas J, Muñoz-Ubeda M *et al.* Statin Therapy in Very Old Patients: Lights and Shadows. Frontiers in cardiovascular medicine 2021; 8:779044. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34912868>
12. Ábrego-Gacía A, Poggi-Varaldo HM, Robles-González V *et al.* Lovastatin as a supplement to mitigate rumen methanogenesis: an overview. J Anim Sci Biotechnol 2021; 12:123. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34911584>
13. McKinley EC, Bittner VA, Brown TM *et al.* Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction. J Clin

- Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34848176>
14. Warden BA, Cardiology BA, Purnell JQ *et al.* Real-world utilization of bempedoic acid in an academic preventive cardiology practice. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34924351>
 15. Heidari B, Babaei M, Yosefghabri B. Prevention of Osteoarthritis Progression by Statins, Targeting Metabolic and Inflammatory Aspects: A Review. Mediterr J Rheumatol 2021; 32:227-236. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964026>
 16. Bourguillon RO, Stokes WA, Dorth J, Schmitt NC. Repurposing Statin Drugs to Decrease Toxicity and Improve Survival Outcomes in Head and Neck Cancer. OTO Open 2021; 5:2473974x211065715. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34917872>
 17. Grabarek BO, Boroń D, Morawiec E *et al.* Crosstalk between Statins and Cancer Prevention and Therapy: An Update. Pharmaceuticals (Basel, Switzerland) 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959621>
 18. Gnanenthiran SR, Agarwal A, Patel A. Frontiers of cardiovascular polypills: From atherosclerosis and beyond. Trends Cardiovasc Med 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973412>
 19. Guo YF. (Improving the prevention and treatment of cardiovascular disease through strictly controlling the risk factors: interpretation of the 2021 ESC clinical practice guide for cardiovascular disease prevention). Zhonghua xin xue guan bing za zhi 2021; 49:1244-1246. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34905905>

Safety and side effects

1. Sunaga T, Ryo Y. Potential Safety Signals for Rhabdomyolysis Associated With High-Potency Statin Use With or Without Sacubitril/Valsartan. Am J Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963512>
2. You HS, Shin SJ, Kim J, Kang HT. Statin Use and Incidence of Chronic Kidney Disease in Hypercholesterolemia Patients with Normal Renal Function. Am J Nephrol 2021; 52:940-948. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34864729>
3. Peersen K, Munkhaugen J, Sverre E *et al.* Clinical and psychological factors in coronary heart disease patients with statin associated muscle side-effects. BMC Cardiovasc Disord 2021; 21:596. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34915854>
4. Saul H, Gursul D, Cassidy S *et al.* Statins do not commonly cause muscle pain and stiffness. Bmj 2021; 375:n3060. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965931>
5. Samura M, Takada K, Hirose N *et al.* Incidence of elevated creatine phosphokinase between daptomycin alone and concomitant daptomycin and statins: A systematic review and meta-analysis. Br J Clin Pharmacol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34902879>
6. Lv Y, Xu B, Zhang X *et al.* Association of serum cholesterol with Parkinson's disease in a cohort of statin-free individuals. Brain and behavior 2022; 12:e2454. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34894416>
7. Shehryar M, Ashraf MF, Uzair Ahmad R *et al.* Statin-Induced Thrombocytopenia in a Young Female: A Case Report and Literature Review. Cureus 2021; 13:e19436. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34909340>
8. Felder M, Maushart CI, Gashi G *et al.* Fluvastatin Reduces Glucose Tolerance in Healthy Young Individuals Independently of Cold Induced BAT Activity. Frontiers in endocrinology 2021; 12:765807. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34858338>
9. Hwang S, Ko JW, Lee H *et al.* Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects. Frontiers in pharmacology 2021; 12:754849. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34867368>

10. Kidambi BR, Purohit V, Bajpai S *et al.* Is the use of high-intensity atorvastatin associated with memory impairment? Indian Heart J 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34933015>
11. Kiage J, Venkatanarayan A, Roth M, Elam M. Atorvastatin-associated rhabdomyolysis in a patient with a novel variant of the SLCO1B1 gene: A case report. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34887219>
12. Feng X, Tang Q, Cheng C, Xu S. Low serum lipid levels, use of statin and cerebral microbleeds: A systematic review and meta-analysis. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2021; 94:216-225. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34863441>
13. Saito J, Kaneko K, Abe S *et al.* Pravastatin concentrations in maternal serum, umbilical cord serum, breast milk and neonatal serum during pregnancy and lactation: A case study. Journal of clinical pharmacy and therapeutics 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34951046>
14. Kuhlman AB, Mikkelsen LB, Regnersgaard S *et al.* The effect of 8 weeks of physical training on muscle performance and maximal fat oxidation rates in patients treated with simvastatin and coenzyme Q10 supplementation. J Physiol 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34891216>
15. Slomski A. Statin Use Is Associated With Diabetes Progression. Jama 2021; 326:2120. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34874431>
16. Chang JC, Chen YJ, Chen IC *et al.* Perinatal Outcomes After Statin Exposure During Pregnancy. JAMA network open 2021; 4:e2141321.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34967881>
17. Bannay A, Bories M, Le Corre P *et al.* Leveraging National Claims and Hospital Big Data: Cohort Study on a Statin-Drug Interaction Use Case. JMIR Med Inform 2021; 9:e29286. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34898457>
18. Safi T, Wagner H. (Two cases of statin-induced immune-mediated necrotizing myopathy). Lakartidningen 2021; 118. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34861042>
19. Atorvastatin. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
20. Simvastatin. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
21. Pravastatin. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
22. Statins. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
23. Lovastatin. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
24. Fluvastatin. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
25. Rosuvastatin. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.

26. Pitavastatin. In: *LiverTox: Clinical and Research Information on Drug-Induced Liver Injury*. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
27. Amarenco P, Kim JS, Labreuche J *et al*. Intracranial Hemorrhage in the TST Trial. *Stroke* 2022; 53:457-462. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963300>
28. Min HK, Kim SH, Choi JH *et al*. Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data. *World journal of clinical cases* 2021; 9:10198-10207. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34904090>

Stroke and CNS

1. Liu M, Zhang Z, Zhao Y *et al*. Combining ultrasound with bio-indicators reveals progression of carotid stenosis. *Ann Palliat Med* 2021; 10:11539-11547. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34872279>
2. Lv Y, Xu B, Zhang X *et al*. Association of serum cholesterol with Parkinson's disease in a cohort of statin-free individuals. *Brain and behavior* 2022; 12:e2454. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34894416>
3. Olmastroni E, Molari G, De Beni N *et al*. Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies. *Eur J Prev Cardiol* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34871380>
4. Freire de Carvalho J, Brandão Neto R, Skare T. Thrombotic microangiopathy in primary antiphospholipid syndrome is linked to stroke and less deep venous thrombosis. *Eur Rev Med Pharmacol Sci* 2021; 25:7369-7374. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34919237>
5. Sun T, Yuan YK, Wu K *et al*. Effects of postoperative atorvastatin use in elderly patients with chronic subdural hematoma. *Eur Rev Med Pharmacol Sci* 2021; 25:7211-7217. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34919219>
6. Beltrán Romero LM, Vallejo-Vaz AJ, Muñoz Grijalvo O. Cerebrovascular Disease and Statins. *Frontiers in cardiovascular medicine* 2021; 8:778740. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34926626>
7. Feng X, Tang Q, Cheng C, Xu S. Low serum lipid levels, use of statin and cerebral microbleeds: A systematic review and meta-analysis. *Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia* 2021; 94:216-225. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34863441>
8. Lewis MM, Albertson RM, Du G *et al*. Parkinson's Disease Progression and Statins: Hydrophobicity Matters. *Journal of Parkinson's disease* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958045>
9. Amarenco P, Kim JS, Labreuche J *et al*. Intracranial Hemorrhage in the TST Trial. *Stroke* 2022; 53:457-462. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963300>
10. Jiang RC, Wang D, Zhao SG *et al*. Atorvastatin combined with dexamethasone in chronic subdural haematoma (ATOCH II): study protocol for a randomized controlled trial. *Trials* 2021; 22:905. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34895306>
11. Xi N, Wang Y, Zhou J *et al*. (Influence of ApoE gene polymorphisms on therapeutic effects of lipid-lowering statins among patients with ischemic cerebral infarction). *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 2022; 39:94-98. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964977>

Triglycerides/HDL

1. Furtado JD, Ruotolo G, Nicholls SJ *et al.* Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease. Arterioscler Thromb Vasc Biol 2022; 42:227-237. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34937388>
2. Bermudez-Lopez M, Perpiñan H, Amigo N *et al.* Advanced lipoprotein parameters could better explain atheromatosis in non-diabetic chronic kidney disease patients. Clinical kidney journal 2021; 14:2591-2599. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950470>
3. Taha H, Kandil H, Farag N *et al.* Egyptian practical guidance in hypertriglyceridemia management 2021. The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology 2021; 73:107. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34928475>
4. van der Laarse A, Cobbaert CM. Biochemical risk factors of atherosclerotic cardiovascular disease: from a narrow and controversial approach to an integral approach and precision medicine. Expert Rev Cardiovasc Ther 2021; 19:1085-1096. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34937476>
5. Cainzos-Achirica M, Quispe R, Dudum R *et al.* CAC for Risk Stratification Among Individuals With Hypertriglyceridemia Free of Clinical Atherosclerotic Cardiovascular Disease. JACC. Cardiovascular imaging 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34922873>

Trials

1. Shin KH, Choi HD. Comparison of Efficacy and Safety of Statin-Ezetimibe Combination Therapy with Statin Monotherapy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Studies. Am J Cardiovasc Drugs 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34927215>
2. Wesółowska A, Winiarska H, Owoc J *et al.* Effects of Low-Dose Atorvastatin on the Peripheral Blood Mononuclear Cell Secretion of Angiogenic Factors in Type 2 Diabetes. Biomolecules 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34944529>
3. Antonenko A, Leahy A, Babenko M, Lyons D. Low dose hydrophilic statins are the preferred agents for females at risk of osteoporosis. Bone Rep 2022; 16:101152. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34934779>
4. Ellimuttill TM, Harrison K, Rollins AT *et al.* Effect of Statin Intensity on the Progression of Cardiac Allograft Vasculopathy. Card Fail Rev 2021; 7:e15. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950505>
5. Gaitán-Duarte HG, Álvarez-Moreno C, Rincón-Rodríguez CJ *et al.* Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. EClinicalMedicine 2022; 43:101242. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957385>
6. Sammons E, Hopewell JC, Chen F *et al.* Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. Eur Heart J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34910136>
7. White HD, Schwartz GG, Szarek M *et al.* Alirocumab after acute coronary syndrome in patients with a history of heart failure. Eur Heart J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34922353>
8. Sun T, Yuan YK, Wu K *et al.* Effects of postoperative atorvastatin use in elderly patients with chronic subdural hematoma. Eur Rev Med Pharmacol Sci 2021; 25:7211-7217. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34919219>

9. Park J, Kang H, Choi YS *et al.* Prevention of Intra-Abdominal Adhesions Using the Combination of Mediclore® and a Statin. Eur Surg Res 2021;1-9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34864732>
10. Wu Y, Li F, Wang Y *et al.* Standard-Dose Atorvastatin Treatment in Patients With Symptomatic Middle Cerebral Artery Atherosclerotic Stenosis: A Vessel Wall Magnetic Resonance Imaging Study. Frontiers in neurology 2021; 12:693397. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956036>
11. Gao J, Liu JY, Lu PJ *et al.* Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol. Front Physiol 2021; 12:750872. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34887772>
12. Mehrabi S, Torkan J, Hosseinzadeh M. Effect of atorvastatin on serum periostin and blood eosinophils in asthma - a placebo-controlled randomized clinical trial. J Int Med Res 2021; 49:3000605211063721. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34904467>
13. Kuhlman AB, Mikkelsen LB, Regnersgaard S *et al.* The effect of 8 weeks of physical training on muscle performance and maximal fat oxidation rates in patients treated with simvastatin and coenzyme Q10 supplementation. J Physiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34891216>
14. Thompson W, Morin L, Jarbøl DE *et al.* Statin Discontinuation and Cardiovascular Events Among Older People in Denmark. JAMA network open 2021; 4:e2136802. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34854906>
15. Lee WM, Bae JH, Chang Y *et al.* Effect of Nutrition Education in NAFLD Patients Undergoing Simultaneous Hyperlipidemia Pharmacotherapy: A Randomized Controlled Trial. Nutrients 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960005>
16. Du L, Jia JH, Xue WY, Qi JC. Effect of tadalafil combined with atorvastatin on hemodynamics and sexual function in middle-aged and elderly patients with hyperlipidemia complicated with erectile dysfunction. Pak J Med Sci 2021; 37:1965-1971. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34912427>
17. Tu Y, Zhang J, Zhang M *et al.* Effect of the therapy of amiodarone combined with atorvastatin on cardiac function of patients with acute myocardial infarction after percutaneous coronary intervention (PCI). Pak J Pharm Sci 2021; 34:2035-2040. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34862870>
18. Matei SC, Matei M, Anghel FM *et al.* Impact of statin treatment on patients diagnosed with chronic venous disease. Morphological analysis of the venous wall and clinical implications. Phlebology 2021:2683555211053566. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34877912>
19. Amarenco P, Kim JS, Labreuche J *et al.* Intracranial Hemorrhage in the TST Trial. Stroke 2022; 53:457-462. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963300>
20. Jiang RC, Wang D, Zhao SG *et al.* Atorvastatin combined with dexamethasone in chronic subdural haematoma (ATOCH II): study protocol for a randomized controlled trial. Trials 2021; 22:905. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34895306>
21. Jull A, Lu H, Jiang Y. Statins and venous leg ulcer healing: Secondary analysis of data from a cohort of three randomised controlled trials. Wound repair and regeneration : official publication of the Wound Healing Society (and) the European Tissue Repair Society 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34894034>

Women and elderly

1. Wylie LE, Waterbrook AL, Dalen JE. Are Statins Indicated in Senior Citizens? A Review of Statin Therapy in the Elderly. *Am J Med* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34856186>
2. Nguyen HT, Ha KPT, Nguyen AH *et al.* Non-achievement of the Low-Density Lipoprotein Cholesterol Goal in Older Patients with Type 2 Diabetes Mellitus and a Very High Cardiovascular Disease Risk: A Multicenter Study in Vietnam. *Ann Geriatr Med Res* 2021; 25:278-285. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34865341>
3. Bergami M, Cenko E, Yoon J *et al.* Statins for primary prevention among elderly men and women. *Cardiovascular research* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34864917>
4. Cobos-Palacios L, Sanz-Cánovas J, Muñoz-Ubeda M *et al.* Statin Therapy in Very Old Patients: Lights and Shadows. *Frontiers in cardiovascular medicine* 2021; 8:779044. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34912868>
5. Kardas P, Lichwierowicz A, Urbański F *et al.* Prevalence of Chronic Polypharmacy in Community-Dwelling Elderly People in Poland: Analysis of National Real-World Database Helps to Identify High Risk Group. *Frontiers in pharmacology* 2021; 12:739740. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34867347>
6. Saito J, Kaneko K, Abe S *et al.* Pravastatin concentrations in maternal serum, umbilical cord serum, breast milk and neonatal serum during pregnancy and lactation: A case study. *Journal of clinical pharmacy and therapeutics* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34951046>
7. Chang JC, Chen YJ, Chen IC *et al.* Perinatal Outcomes After Statin Exposure During Pregnancy. *JAMA network open* 2021; 4:e2141321. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967881>
8. Chen J, Huang C, Zhang T *et al.* The effects of statins on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. *Reproductive biology and endocrinology : RB&E* 2021; 19:189. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34930305>



You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.

This activity is supported by an educational grant from Viatrix.
© P.J. Lansberg